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The dissertation uses health related quality of life (HRQoL) for evaluating 
treatment effectiveness. The research settings in the dissertation include 
observational cohort study and randomized clinical trial. The first research project 
examines the effect of Sahaja Yoga Meditation on quality of life. The study 
investigates whether the post intervention HRQoL, perceived anxiety assessment 
and hypertensive control is different in patients treated with meditation plus 
conventional therapy than patients treated with conventional therapy alone. The 
study shows that Sahaja Yoga Meditation treatment is associated with significant 
improvements in quality of life, anxiety reduction and blood pressure control. 
The second research project examines the association of age on clinical and 
quality of life outcomes in the Bypass Angioplasty Revascularization Investigation 2 
Diabetes Trial (BARI 2D); specifically, among patients with both type 2 diabetes and 
coronary heart disease, whether a treatment strategy (prompt revascularization or 
medical therapy for heart disease and insulin sensitizing or insulin providing drugs 
for type 2 diabetes) is more preferable for older individuals in terms of clinical and 
HRQoL endpoints. The study shows that older patients are at greater risk for 
cardiovascular events but the effectiveness of cardiac treatment strategies and 
glycemic control strategies does not differ by age. Older patients experience an 
accelerated decline in health status than their younger peers. 
The third research project investigates the longitudinal relationship between 
body mass index (BMI) and heath status outcomes in BARI 2D. The study reports an 
inverse association between BMI and health status outcomes in patients with both 
stable ischemic heart disease and type 2 diabetes. Weight reduction is desirable for 
obese patients, but may not be necessary for overweight but non-obese patients to 
achieve improvements in functional capacity and perceived Energy outcomes. 
 v
The public health significance of the dissertation lies in the research findings on 
treatments that result in better clinical or quality of life outcomes for patients with 
chronic diseases, but also contrasts the strength and weakness of HRQoL studies 
and demonstrates strategies to overcome the methodological challenges in 
conducting HRQoL research in clinical studies.  
 vi
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1. Dissertation overview and objectives 
To evaluate the effect of treatment on the health and well being of the patients, 
measures of health related quality of life (HRQoL) are frequently incorporated as 
outcomes in clinical studies. Studying HRQoL in clinical research is complicated by 
the setting, therapeutic practices of interest, and design of the study. This 
dissertation uses HRQoL to evaluate treatment effectiveness in two different 
settings—a pilot study and a randomized clinical trial, and elucidates challenges in 
HRQoL study and approaches to address these challenges.   
The dissertation is composed of three research topics. The first topic evaluates 
the effect of Sahaja Yoga Meditation on HRQoL. This research was conducted using 
an observational prospective cohort design. The second and third research topics 
are conducted within the framework of the Bypass Angioplasty Revascularization 
Investigation 2 Diabetes Trial (BARI 2D), a randomized clinical trial evaluated 
treatment strategies for patients with both stable ischemic heart disease and type 2 
diabetes. Health status is a secondary outcome in the research to support the 
primary findings on clinical endpoints. The second research topic investigates the 
association between age, randomized treatment assignment and clinical and health 
status outcomes. The third research topic investigates the longitudinal relationship 
between body mass index (BMI) and health status. 
The dissertation compares and contrasts the strengths and weaknesses of 
HRQoL studies in observational study and randomized clinical trial settings. In the 
last part of the dissertation, a research proposal for evaluating the effect of 
meditation on clinical and HRQoL outcomes is presented for future study. 
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2.  Introduction 
2.1 Evaluating treatment effectiveness for chronic diseases 
One specific objective in epidemiology is to evaluate preventive and therapeutic 
interventions.1 When a physician suggests a treatment to a patient, the decision-
making is based on the experience with large groups of patients who had the same 
disease, the treatments these patients received, and the prognosis of the treatment 
being observed. Consequently, the key elements in epidemiology studies for 
treatment evaluation include the study design, sample population, intervention being 
evaluated, and effectiveness outcomes.  
Study design:  A randomized controlled trial remains the optimal design for 
evaluating therapeutic practices. Ideally, randomization will generate groups of 
participants that are balanced over demographic or clinic characteristics; as a result, 
the difference in outcomes is mainly attributed to the intervention being evaluated. 
Observational studies, such as longitudinal cohort and case control study, remain 
necessary to generate hypotheses and gather pilot data for the planning of 
randomized trials.  Observational studies can complement or strengthen the findings 
of randomized trials. In general, observational studies include broader or more 
“generalizable” study populations since study participants do not have to consent to 
randomization; however, the received treatment in observational studies is often 
biased such that treatments are selected based on the patient’s clinical profile 
referred to as “confounding by indication.”  A recent meta-analysis reported 
consistent findings from well-designed observational studies and randomized trials 
for acute or chronic diseases. The authors summarized that the results from well-
designed observational studies and randomized trials were comparable.2 
Study population:  The challenge in selecting a study population in a 
randomized trial is to identify proper inclusion and exclusion criteria, so that the study 
population resembles the characteristics of the target population. In observational 
studies, the study population for cohort studies is either selected by recruiting the 
exposed and/or non-exposed individuals or by identifying a defined population before 
exposures occur and follow this population over time, a classic example of this is the 
Framingham study.1 In case control studies, cases can be identified from hospital 
records or disease registries. The selection of controls usually follows one of the two 
approaches—either selecting controls that resemble cases in all aspects but the 
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disease of interest, or selecting controls that represent all persons without the 
disease in the target population. 
Study Interventions: Drugs, medical devices, surgical practices, and lifestyle 
modification are examples of interventions, treatments or treatment strategies that 
are frequently evaluated in clinical research.3  
Study Outcomes:  The selection of study outcomes depends on biology, study 
setting, the intervention being evaluated, and the objective of the clinical study.3 A 
good outcome has qualities such as clinical relevance, ability to be quantified, and 
being valid, objective, reliable, sensitive, and precise.3 The primary outcome often 
determines both the study design and analysis approach. A primary outcome is 
usually an assessment of clinical importance, such as survival. In clinical studies, it is 
not uncommon to have multiple secondary outcomes to evaluate different aspects of 
the treatment effect. A common purpose of using secondary outcomes is to support 
the finding of primary outcome. Quality of life measures are often used as a 
secondary outcome in clinical studies.  
 
2.2 Health related quality of life as outcomes for treatment evaluation 
       "Health-related quality of life" (HRQoL) integrates aspects of physical, 
psychological, and social health, as defined by the World Health Organization in 
1948. 4, 5 HRQoL can be altered by both the immediate and long-term treatment 
effects, especially in the chronic disease setting. Patients with chronic conditions 
often suffer from prolonged physical and psychological distress, which deteriorates 
quality of life. 6  The estimated advantage of one treatment over another can be 
substantially altered, or even reversed, by adjusting the primary effectiveness 
endpoints by quality of life. For example, Croog et al compared three anti-
hypertensive therapies in a randomized clinical trial, while the three treatments 
showed no difference in the primary outcome, the results showed major differences 
in HRQoL.7  In the cancer chemotherapy trial, Buccheri et al. suggested that small 
treatment benefits may be more than outweighed by the poorer quality of life and 
cost of therapy.8 
       In chronic diseases where a cure is not easily achieved, the goal of treatment is 
to stop the progress of the disease and improve the quality of life of patients.9 It is 
estimated that over 100 million people live with chronic illness in the United States.10 
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Effective interventions that can alleviate the distress and improve quality of life are 
important to the health and well being of the patients. 
 
2.3 Health related quality of life measurements 
There are two major strategies to assess HRQoL—the assessment based on 
questionnaires regarding the perceived state of health and assessment based on the 
tradeoff between quality and quantity of life. 11,12,13 The first strategy is derived from 
psychometrics, where the perceived wellbeing of an individual is measured by 
his/her responses to a series of questions measuring different aspects of HRQoL; it 
is the preferable HRQoL measurement in clinical studies because of its simplicity in 
implementation.11 
 
2.3.1 Properties of HRQoL measurements 
Common properties in all forms of HRQoL measurements include coverage, 
validity, reliability, responsiveness and sensitivity.4 Coverage describes the ability of 
a HRQoL measurement to evaluate components that are important and susceptible 
to change by the intervention. The components can be both objective and subjective, 
such as symptoms, health status, or perceived psychological or social well being. 
Reliability is the ability for a HRQoL measurement to yield stable values in constant 
conditions. In a longitudinal setting with repeated assessments, reliability also 
applies to the ability for an instrument to capture the true change over time. 4,11,14 
Validity is the ability of HRQoL measurements to measure what they claim to 
measure. Aspects of validity include face validity, construct validity and discriminant 
validity.11 Face validity refers to whether the content of an instrument can be 
comprehended clearly without ambiguity.11 Construct validity describes whether the 
results derived from the instrument are as expected to be relative to other reliable 
measurements assessing related characteristics. Or whether there is no association 
between results of measurements assessing unrelated characteristics, for example, 
a measurement of physical activity is expected to be correlated with another 
physiological measure than an measure for environment.11,14 The comparison with 
other reliable measures for construct validity assessment is needed due to the lack 
of gold standard for measuring HRQoL. Discriminant validity represents the ability of 
the instrument to distinguish among subjects who experience different levels of 
HRQoL, for example one expects to observe worse HRQoL for patients with more 
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severe symptoms or other adverse disease measures. Discriminant validity is 
sometimes referred as responsiveness.4,11 
Sensitivity is the ability of a measure to reflect true changes or differences in the 
underlying construct of wellbeing which the HRQoL measurement being used to 
assess. Problems such as an inadequate range, delineation of the response, ceiling 
and floor effects in measurements can mask important and therapeutically 
meaningful changes in HRQoL.11,14 In addition, longitudinal changes within a patient 
are typically smaller than differences between patients, and therefore clinical studies 
with repeated HRQoL assessments during follow up require a greater sensitivity of 
the measurement.11 
 
2.3.2 Generic HRQoL Measurements 
Generic measurements are used in the general populations, irrespective of the 
heterogeneity in illness or health condition, to assess a wide range of domains 
applicable to a variety of health states and diseases. 15  Generic HRQoL 
measurements are commonly used in general health surveys and can be used to 
make comparisons between disease states. In clinical trials, using generic 
measurement also enables the investigators to compare the perceived HRQoL 
between study patients and other established patient or healthy populations as well 
as compare HRQoL between the active treatment phase and extended follow up 
periods after treatment has ended.11 Examples of common generic HRQoL 
instruments include the Sickness Impact Profile, 16  Nottingham Health Profile, 17 
Medical Outcomes Study 36-item Short Form,15 EQ-5D, 18  and the World Health 
Organization Quality of Life questionnaire.19 
 
2.3.3 Disease Specific HRQoL Measurement 
       Disease-specific instruments are developed to detect subtle effects for a 
particular disease and the common treatments used for this disease.  These 
measures provide detailed information on clinically relevant HRQoL change. Items in 
diseases specific measurements are designed to assess aspects such as symptoms, 
treatment satisfaction, and the impact of the disease on emotional, physical, and 
social well being.11,14 In clinical trials, disease specific instruments are chosen 
because it is expected to have better sensitivity to the health states that may be 
experienced by patients in the study. Examples of HRQoL measures for patients with 
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coronary artery disease include the Duke Activity Status Index,20 the Seattle Angina 
Questionnaire.21 Examples of HRQoL measures for patients with diabetes include 
the Appraisal of Diabetes Scale22 and Diabetes Health Profile.23  
 
2.4   Health related quality of life research in clinical studies 
Important elements in HRQoL research include the specification of the study 
objective, design, measurement selection, data collection and statistical analysis.  
 
2.4.1 Objective   
HRQoL can be assessed as the primary, secondary, or tertiary outcome of 
interest, depending on the objective of the study, In clinical studies where HRQoL is 
a primary outcome, the efficacy of intervention is based on some or all of the 
dimensions of HRQoL.11 In most studies, it is also common to use HRQoL as the 
secondary endpoints to support the primary clinical findings. Other than measuring 
effectiveness, subscales of HRQoL measurements, such as the physical functioning 
and bodily pain subscales of SF-36, can be used as the tertiary outcomes to monitor 
the safety of the therapeutic intervention.11 
 
2.4.2 Design  
A longitudinal design is frequently used in clinical studies to determine the effect 
of a therapy on changes in HRQoL status overtime.11 The optimal number and timing 
of HRQoL assessments depends on the disease, therapeutic practices, and the 
study question. In a randomized clinical trial, the initial HRQoL assessment should 
occur prior to randomization, and follow-up HRQoL assessment should be frequent 
enough to capture meaningful change, but not to an extent that increases 
respondent burden, nor be more frequent than the period of recall of the 
measurement.11 
 
2.4.3 Selection of HRQoL measurement 
In the definition of Guyatt et al, a HRQoL instrument includes the questionnaire, 
method of administration, instructions for administration, method of scoring, data 
analysis and interpretation.24 All of these aspects are important in selecting a HRQoL 
instrument for a clinical study. Developing a new instrument involves tasks including 
item generation, cognitive interviews, pre-testing, item reduction, validation studies, 
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translation, and cultural adaptation, a process that takes years to complete.11,14 
Therefore, it is highly recommended to use a previously validated instrument rather 
than a new, unvalidated one for HRQoL assessments in clinical studies.  
The choice of selecting a generic measurement, disease-specific measurement 
or a combination of both is based on the attempt to compile a complete set of 
HRQoL questions that are most relevant to the disease and interventions being 
evaluated.4,11 It is also common for clinical studies to use subscales of the generic or 
disease-specific measurements to compile a survey instrument tailored to the study 
question. The selection of HRQoL measurements in clinical studies is not yet 
standardized, largely due to the diverse HRQoL aspects being assessed in different 
clinical studies. Consequently, HRQoL results from different studies are not 
comparable, and it is difficult to interpret HRQoL results across studies.25 
 
2.4.4 Conduct Assessment 
In clinical studies, administration of HRQoL measurements include self-
assessment, face to face assessments or centralized telephone interview with 
trained interviewers.11 Different modes of administration may influence the HRQoL 
result. For example, self-report assessment may result in more non-response items 
where as direct interview methods increase the likelihood for patients to report social 
desirable responses during interview.14 To manage this discrepancy, sensitivity and 
cares to be given to patients so that they can feel comfortable being honest with the 
investigator regarding HRQoL answers. It is also useful to incorporate social 
desirable responses measures in HRQoL questionnaires.  
 
2.4.5 Missing Data during Implementation 
Shortages in time of the research staff, lack of physician support, inadequate 
protocols, and unaware of the rationale for collecting HRQoL data all contribute to 
missing HRQoL data in the implementation stage of clinical studies.11 Precautions for 
avoiding missing data during data collection include clearly specifying in the protocol 
the procedures for collecting HRQoL information, communication with patients about 
the importance to complete HRQoL assessments, and communicating with research 
assistants and investigators about the rationale of collecting HRQoL assessments 
and the importance of collecting data on all patients willing to complete the 
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questionnaire. Regular meeting helps identify and address the difficulty and 
reluctance faced by the research team in HRQoL data collection. 
The secondary prevention for missing data is to gather information on factors 
that may contribute to missingness. Such information will be helpful in specifying the 
missing mechanism and accounting for the missing data in the analysis.11  
 
2.4.6 Analytical Considerations 
In a longitudinal study where HRQoL is measured repeatedly over time, multiple 
measures on the same participant tend to be correlated, and the difference in each 
measurement from population mean is not solely explained by random variation. 
Thus, simple linear regression and ANOVA/MANOVA models are not sufficient. An 
approach such as mixed effects models can effectively account for the within-person 
correlation by using a covariance structure to model the pattern of covariance 
between repeated observations, or by incorporating a random intercept and random 
coefficient to account for the deviation of the intercept and regression slope of each 
individual from the population averaged ones.26 
 
2.4.7 Missing Data 
Missing data is common in longitudinal study, due to the free will of the 
individual and the various levels of morbidity and treatment complication experienced 
by patients.27 A broader definition of “missing data” refers to no information obtained 
at the time of a scheduled assessment; the assessment may or may not be required 
by protocol. Examples of missing data patterns include: 1) attrition, where no 
assessment is expected since HRQoL assessment was terminated as specified in 
the protocol; 2) noncompliance, where no assessment is obtained when it is 
expected per protocol; 3) dropout, the discontinuation of the outcome measures.11 
Missing data introduce complications in HRQoL study results, from a decrease in 
statistical power to detect differences to bias in study results and interpretation.11 
Analysis strategies can adapt different assumptions on the mechanism of 
missing HRQoL outcomes, and remedy the effect of missingness to some extent. 
The common assumptions for the mechanism of missing outcomes include missing 
completely at random (MCAR), missing at random (MAR), and missing not at 
random (MNAR).  
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MCAR assumes the reason for a missing HRQoL assessment is entirely 
unrelated to the HRQoL level or values.28 It is a strong assumption and is often not 
appropriate in HRQoL studies, for example, if patients with prior low HRQoL are less 
likely to answer HRQoL questions, the MCAR assumption is violated.14,27 MCAR is 
the missing assumption for longitudinal statistical procedure such as the generalized 
estimating equations (GEE).28  
       MAR relaxes the missing data assumption by allowing missing HRQoL data to 
depend on observed covariates and observed HRQoL scores. This means that 
missing data may be related to factors such as older age, gender, duration of 
diabetes as well as prior HRQoL level, but conditioning on the observed patient 
profile and prior HRQoL values, the future missing data is completely random.  MAR 
is the assumption for missing outcomes in mixed model analysis.  
MNAR describes missingness that is dependent not only on known covariates 
and prior outcomes, but also on the unobserved missing data at the time the 
assessment.27 Thus, if sudden changes in health status that are not assessed cause 
missing HRQoL data, this results in MNAR. Strategies exist, such as utilizing pattern-
mixture models, to manage the missing outcomes that are assumed to be MNAR.  
Complications of missing data also arises from excluding individuals with 
missing baseline or no follow up assessments from the longitudinal analysis. The 
common practice of excluding participants who either die early or are too sick to 
complete the first follow-up assessment leads to HRQoL measures that may over-
estimate the true values. The impact of missing outcomes from such patients on 
results can be evaluated by sensitivity analysis with proper imputations.  
 
2.4.8 Multiple Testing 
If analyses involve four or five HRQoL outcomes, there will be concerns about 
false statistical significance as a consequence of multiple testing.14 One way of 
avoiding this problem is to identify in the protocol one or two primary HRQoL 
outcomes of principal interest, and reporting nominal p values for statistical testing 
with the notification of multiple testing problem in the discussion, as recommended 
by Pernegger 29  and Fayers and Machin.14 It may be preferable to use a 99% 
confidence interval as an aid to interpretation of the results.11   
Another common practice of managing multiple testing is to adopt an adjusted 
alpha level using methods such as the Bonferroni correction. For example, in a 
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clinical study with five HRQoL outcomes, the alpha level after Bonferroni correction 
is 0.05/5=0.01, can be used as the final p-value denoting “statistical significance” for 
the individual tests.11,14 
3.  Examples of health related quality of life research in clinical studies 
This dissertation is composed of three research topics involving HRQoL 
research in clinical studies. The first research topic evaluated the effect of Sahaja 
Yoga Meditation on HRQoL with an observational prospective cohort design. The 
second and third projects were conducted within the framework of BARI 2D, a 
randomized clinical trial designed to evaluate the treatment strategies for patients 
with both stable ischemic heart disease and type 2 diabetes. Data on the health 
status aspects of HRQoL were collected as the secondary outcome in BARI 2D. 
  
3.1 Literature review on the effect of meditation therapy on health related quality of 
life outcomes 
       Few studies in the current literature have documented the effect of meditation or 
yoga on quality of life. Reibel et al compared the change in quality of life before and 
after a mindfulness meditation program in 136 patients with various health 
conditions.30 The study reported clinically meaningful improvement in quality of life, 
as defined by a 5 point or greater increase in SF-36 scales, in role-physical, vitality, 
role-emotional, mental health subscales and mental component summary measure, 
associated with the meditation program. Since there was no control group, however, 
it was difficult to know the extent of improvement in quality of life that was directly 
attributable to the meditation.  
       In a pilot study conducted by Curiati et al, elderly patients with optimally treated 
congestive heart failure were randomized to receive meditation or not. The 
meditation technique was a combination of complete yoga breathing, relaxation 
response and guided image of a healthy heart. Quality of life was measured by the 
Minnesota Living with Heart Failure Questionnaire. The study reported a higher level 
of quality of life associated with meditation which was equivalent to the difference 
achieved between enalapril treatment versus placebo in a previous study.31 However, 
the inference was based on 19 patients, the small sample size increased the risk of 
chance finding in the study.   
        Another factorial randomized trial was conducted to compare the effect of 
adding Metta (love-kindness) meditation and massage to standard therapy on quality 
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of life among patients with advanced AIDS. The study reported significantly better 
quality of life, measured by Missoula-Vitas QoL Index, in the group that received 
both meditation and massage. However, adding either meditation or massage to 
standard therapy did not significantly improve the quality of life compared to standard 
therapy alone.  The study did not acquire sufficient statistical power to distinguish 
whether the beneficial effect resulted from meditation alone, massage alone, or the 
synergistic effect of the two interventions.32 
       Among healthy individuals, Oken et al conducted a randomized trial, assigning 
healthy seniors to one of three groups: Iyengar yoga, aerobic exercise or wait-list 
control. Quality of life was a secondary outcome in the study. The Iyengar yoga 
group demonstrated significantly better scores for SF-36 vitality, role-physical, bodily 
pain, social functioning subscales, and the physical composite summary.33 
       In conclusion, there are few studies that explored the effect of meditation/yoga 
on quality of life, and the strength of evidence from most of these studies is 
undermined by suboptimal study designs and insufficient power. Rigorous evidence 
on how meditation influences quality of life, especially in clinical settings, is absent in 
the current literature.  
 
3.2 Review of health related quality of life studies in randomized clinical trials for 
coronary heart disease or type 2 diabetes  
The HRQoL study in the original BARI trial reported a greater functional capacity 
during the first three years for patients who had stable heart disease and were 
randomized to receive bypass surgery, as compared to angioplasty.34 It is notable 
that the difference in HRQoL results between treatment groups was not significant at 
5 or 10 years after randomization, as the rate of recurrent angina, which was 
negatively associated with HRQoL outcomes, converged between the treatment 
groups.35 A similar trend was observed in the COURAGE trial, where patients with 
stable coronary artery disease were randomized to receive either percutaneous 
coronary interventions (PCI) or medical therapy. A greater HRQoL improvement, 
measured by RAND-36 survey instrument, was observed in patients with more 
severe angina. PCI resulted in better HRQoL outcomes than medical therapy, but 
the difference between treatment groups diminished after 3 years of follow-up.36 
Similarly, the ACME trial reported a better HRQoL for patients randomized to receive 
PCI compared with medical therapy at 6 month of follow-up.37 In RITA-2 trial, greater 
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HRQoL improvement was observed in the PCI than in the medical therapy group.38 
The MASS II trial compared effectiveness among three treatment strategies—the 
bypass surgery, PCI and medical therapy, in patients with stable multi-vessel 
coronary heart disease. The greatest improvement in HRQoL was observed in 
patients randomly assigned to receive bypass surgery.39 In patients with unstable 
angina, the RITA-3 trial reported better HRQoL outcomes in the revascularization 
than medical therapy group at year one.40 The positive effect of revascularization on 
HRQoL outcomes may be attributable to the greater capacity of revascularization to 
relieve angina in patients than medical therapy. The diminishing HRQoL difference in 
treatment groups may be partly explained by the increasing revascularization rate in 
the medical group over time which results in angina relief. 
For type 2 diabetes, a cross-sectional survey of follow-up HRQoL in the UKPDS 
study reported no difference in HRQoL by randomized treatment groups. Although 
HRQoL was not used to evaluate the randomized treatment effectiveness, results 
from the study demonstrated an inverse association between HRQoL and diabetic 
complications.41  
In summary, revascularization was associated with preferable intermediate 
HRQoL outcomes than medical therapy in previous randomized clinical trials for 
patients with heart disease. However, few HRQoL results were available in 
randomized clinical trials for type 2 diabetes in the current literature, and information 
on HRQoL outcomes in trials for patients with both heart disease and type 2 diabetes 
are lacking. 
 
4. Introduction of the Bypass Angioplasty Revascularization Investigation 2 
Diabetes Trial (BARI 2D) 
The second and third research topics of the dissertation are based on data from 
the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.  
BARI 2D aimed to investigate optimal treatment strategies for patients with both 
stable ischemic heart disease and type 2 diabetes. BARI 2D was designed to test 
the two hypotheses—1) whether prompt coronary revascularization combined with 
medical therapy decreased the long-term mortality compared with medical therapy 
with the option of delayed revascularization when clinically indicated and 2) whether 
controlling serum glycosylated hemoglobin (HbA1c) level to a target of less than 
7.0% with insulin sensitizing drugs decrease the long-term mortality compared with 
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insulin providing drugs.42 To simultaneously test the two hypotheses, the BARI 2D 
trial used a 2 by 2 factorial design, where patients were randomly assigned to one of 
the two ischemic treatment strategies and one of the two glycemic treatment 
strategies. 
 
4.1 Study Population 
The study population in the BARI 2D trial is patients with both type 2 diabetes and 
angiography documented stable ischemic heart disease to be managed either by 
revascularization or medical therapy. The recruitment of BARI 2D trial began with 
seven vanguard sites in the United States on January 1, 2001 and ended on March 
31, 2005 with 49 clinical sites located in the US, Canada, Mexico, Brazil, Austria and 
Czech Republic. A total of 2,368 patients gave written informed consent to be 
enrolled in BARI 2D trial. The baseline demographic and clinical characteristic of 
BARI 2D population is summarized in table 1.43  
 
Patient Subgroups 
Before randomization, each consented patient was evaluated by his/her responsible 
cardiologist to determine the revascularization strategy, either Percutaneous 
Coronary Intervention (PCI) or Coronary Artery Bypass Graft surgery (CABG), based 
on the patients clinical profile and extent of coronary disease. The intended 
revascularization strategy was an essential indicator defining the severity of coronary 
disease, and most importantly, the trial randomization was stratified by this intended 
method of revascularization variable (PCI or CABG). Other pre-specified patient 
subgroups were defined based on baseline characteristics including history of 
revascularization, insulin use, HbA1c categories, left ventricular function, creatinine 
level, and race.42 
 
4.2 Study Intervention 
The randomized ischemia control strategies were comprised of: prompt 
revascularization with intense medical therapy versus intense medical therapy with 
delayed revascularization when clinically indicated. According to the protocol, 
patients assigned to the prompt revascularization group should receive the 
revascularization procedure within 4 weeks after randomization. The procedure, 
either coronary artery bypass graft surgery (CABG) or percutaneous coronary 
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intervention (PCI), was selected based on the patient’s clinical and angiographic 
profile.42 
The randomized glycemic control strategies for achieving a target of HbA1c less 
than 7.0% were comprised of: insulin sensitizing versus insulin providing drug 
treatment. Insulin sensitizing drugs included thiazolidinediones (TZD) and metformin. 
Insulin providing drugs included sulfonylurea drugs, repaglinide, nateglinide, and 
insulin.42  
All BARI 2D patients received coronary risk-factor modification including target 
driven medical treatment for dyslipidemia and hypertension, and counseling to 
manage weight control, exercise and smoking cessation,44 
 
4.3 Follow-up  
All patients were followed at monthly clinic visits for the first 6 months and then 
quarterly visits until the end of the study. At each clinical visit, patient assessment 
included glycemic control, medication taken for diabetes, occurrence of adverse 
clinical events, complications, and angina status.42 In addition, patient body weight 
and blood pressure were measured at clinical visit.42 BARI 2D patients were followed 
until November 30, 2008.  Protocol driven treatment was delivered until the 6-year 
annual follow-up visit or the annual follow-up visit that occurred between December 1, 
2007 and November 30, 2008.   
 
4.4 Measures 
Biological Samples for Core laboratory assessments 
Blood samples for core laboratory assessment on HbA1c, fibrinolytic factors, and 
insulin was drawn at baseline, at 1 month, 3 months, 6 months, 1 year, and then 
every 6 months until the end of follow-up. Blood samples for lipid assessment were 
drawn at baseline, 6 months, 1 year, and then annually during follow up. Urine 
samples for core laboratory assessment on albumin and creatinine were collected at 
baseline and then annually during follow-up. 12-lead electrocardiography 
examinations were obtained at baseline, at 3 months, 1 year, and then annually for 
core laboratory assessment. 42 
 
Health Related Quality of life  
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Health related quality of life was assessed at baseline and at each annual clinic 
visit during follow up. The instrument package was a combination of complete scales 
or subscales of self-administered questionnaires, including the Duke Activity Status 
Index (DASI),20 RAND Medical Outcome Study Energy/fatigue and health distress 
scales,45 and self-rated health.46The Center for Epidemiologic Studies Depression 
Scale (CES-D)47 was added to annual follow up assessment after recruitment ended, 
thus no baseline CES-D data available. The four HRQoL measures assessed both at 
baseline and during follow-up years (DASI, Energy, Health distress and Self-rated 
health) were focused on measuring the health status aspect of HRQoL. Therefore, in 
the dissertation, the term “health status measures”, instead of “HRQoL measures” 
were used in the second and third research topics.    
The DASI score ranged from 0-58.2. Self-rated health was measured in a five-
category Likert scale and can be scored as continuous.46 The Energy/fatigue and 
transformed self-rated health scores ranged from 0-100. A higher score for these 3 
scales indicated better health status. In contrast, the health distress score ranged 
from 0-100 and the CES-D ranged form 0-60, and a higher score indicated worse 
health status.  
 
4.5 Study Outcomes 
The primary outcome in BARI 2D was all-cause mortality. Vital status was 
obtained from scheduled clinical visits and annual vital status surveys. In February 
2009, a national database search was conducted to determine whether deaths had 
occurred for patients with unknown vital status.48  
The principal secondary outcome was a composite of death, myocardial 
infarction, or stroke. Diagnosis of myocardial infarction is based on serum cardiac 
biomarker, such as creatine kinase MB (CK-MB) or troponin level, symptoms, and 
core laboratory electrocardiography assessments. Stroke and cause of death were 
adjudicated by an independent morbidity and mortality classification committee that 
were blinded from randomized treatment assignments.48 
 
4.6 Main Findings of BARI 2D 
The primary BARI 2D results demonstrated that there were no significant 
differences in five-year survival rate between the two ischemic treatment strategy 
groups (p=0.97), nor between the two glycemic treatment strategy groups (p=0.13).48 
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Similarly, the differences between randomized treatment groups were not statistically 
significant for the principal secondary outcome of the five-year cumulative rate of 
death/MI/stroke.48  
Comparing the ischemia treatment strategies within the intended 
revascularization strata, the study reported no significant difference in mortality in 
either stratum. For the secondary endpoint of death/MI/Stroke, there was no 
treatment difference observed in PCI stratum; however, in the CABG stratum, the 
rate of death/MI/stroke was significantly lower in the prompt revascularization group 
compared with the medical therapy group (P=0.01).48 
The study concluded that treatment strategies of prompt revascularization or 
medical therapy with delayed revascularization, and insulin provision or insulin 
sensitization result in similar rates of survival and major cardiovascular outcomes 
among patients with both stable ischemic heart disease and type 2 diabetes.48    
Among patients appropriate for CABG, revascularization may confer some benefits 
over initial medical therapy regarding major cardiovascular events.   
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Table 1 Selected Baseline characteristics of BARI 2D population (N = 2368) 43 
Demographic and Physical 
Characteristics Cardiac Status 
Diabetes Status and 
Lipids 
Age, mean 62.4 Hypertension, % 82.5 Duration of DM categories, % 
Male, % 70.4 Hypercholesterolemia, % 81.9  <5 yrs 33.3 
Race, % Cigarette smoking status, %  5 - <10 yrs 23.5 
 White 70.4  Current 12.5  10 - <20 yrs 29.2 
 Black 17  Former 54.4  ≥ 20 yrs 14.1 
 Asian 4.2  Never 33.1 History of insulin use, % 29.3 
 Indian/Native American 4.3 Myocardial infarction, % 32 Glycemia measurements, % 
 Other 4.1 Congestive heart failure, % 6.6  HbA1c ≤ 7.0% 41.7 
Hispanic ethnicity, % 12.5 Non-coronary artery disease, % 23.7 
 7.0% < HbA1c ≤ 
8.0% 25.3 
Region of World, % Stroke or TIA, % 9.8  HbA1c >8.0% 33 
 USA 63.3 Prior PCI, % 19.6 Albuminuria 
 Canada 14.9 Prior stent, % 13.4  Microalbuminuria  22.9 
 Brazil 15 Prior CABG, % 6.4  Macroalbuminuria  9.7 
 Mexico 3.6 Angina status, % ABI≤0.9 20.1 
 Europe 3.2  None 17.9   
BMI categories (kg/m2), %  Angina equivalents only 21.4 MNSI clinical score >2, % 50.3 
 Normal or underweight, 
<25 9.7  Stable CCS 1 14.3 
Total cholesterol 
≥200 mg/dL, % 19 
 Overweight, 25 to <30 34  Stable CCS 2 28.8 Triglycerides ≥200 mg/dL, % 31 
 Class 1 obese, 30 to <35 32.1  Stable CCS 3 7.5 HDL <40 male <50 female mg/dL, % 72.4 
 Class 2 obese, 35 to <40 15.3  Stable CCS 4 1.2 LDL ≥100 mg/dL, % 40.5 
 Class 3 obese, ≥40 9 
 
 Unstable angina 9.5 
 
  
 
TIA, Transient ischemic attack; ACR, albumin to creatinine ratio; HDL, high-density lipoprotein; ABI, Ankle 
brachial index; MNSI, Michigan Neuropathy Screening Instrument; (Table reprint with modification from: Bypass 
Angioplasty Revascularization Investigation 2 Diabetes Study Group. Baseline characteristics of patients with 
diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 
Diabetes (BARI 2D) trial. Am Heart J 2008;156:528-536.) 
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5.  Specific aim  
 
       The aim of the first research project is to examine the effect of Sahaja Yoga 
Meditation on quality of life. The study investigated whether the post intervention 
HRQoL and perceived anxiety assessment is different in patients treated with 
meditation plus conventional therapy compared to patients treated with conventional 
therapy alone. The study also investigated differences in blood pressure and pulse 
for patients with self-report hypertension at baseline. 
 
The aim of the second research project is to examine the association of age on 
clinical and quality of life outcomes; specifically, whether age modifies the effect of 
randomized treatment on clinical and HRQoL endpoints in patients with both stable 
ischemic heart disease and type 2 diabetes.  
 
The aim of the third research project is to investigate the longitudinal 
relationship between body mass index (BMI) and heath status in patients with both 
stable ischemic heart disease and type 2 diabetes.  
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6. Paper one: effect of Sahaja Yoga Meditation on quality of life and anxiety 
 
6.1 ABSTRACT 
OBJECTIVE 
       This study investigated the effect of Sahaja Yoga Meditation on quality of life, 
anxiety level, and blood pressure control among hypertensive patients. 
METHODS 
       A prospective observational cohort study was conducted. The meditation group 
was comprised of patients receiving treatment from the International Sahaja Yoga 
Research and Health Center. The control group was comprised of patients receiving 
treatment from the Mahatma Gandhi Mission Hospital, both located in New Mumbai, 
India. Quality of life, anxiety and blood pressure were measured before and after 
treatment received. 
RESULTS 
During August, 2008, 67 patients in the meditation group, and 62 patients in the 
control group completed the study. The two groups were comparable in demographic 
and clinical characteristics. At baseline, compared to the control group, the 
meditation group had higher quality of life (p<0.001) and similar anxiety level 
(p=0.74); among the subgroup of patients with hypertension, the meditation group 
had lower blood pressure (p<0.001). Within-group pre versus post treatment 
comparisons showed significant improvement in perceived quality of life, anxiety and 
blood pressure control in the meditation group (p<0.001), while quality of life 
deteriorated and no improvement in blood pressure was observed in controls. 
Between-group analyses demonstrated that the meditation group had larger 
improvement in quality of life, anxiety reduction and blood pressure control. The 
beneficial effect of meditation remained significant after adjusting for potential 
confounders. 
CONCLUSIONS 
Sahaja Yoga Meditation treatment was associated with significant improvements 
in quality of life, anxiety reduction and blood pressure control. 
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6.2 INTRODUCTION 
       Quality of life integrates aspects of physical, psychological, and social health.4 
Patients with chronic diseases often suffer from a prolonged physical and 
psychological distress, such as stress and anxiety disorders. This prolonged distress 
is known to affect their quality of life.6 As over 100 million people in the United States 
are living with chronic illness,10 the search for effective interventions that can 
alleviate the distress and improve quality of life is needed.   
During the past 50 years, the use of meditation and yoga, commonly applied as 
an effective adjunct to conventional medical treatment, has increased rapidly in the 
general population. 49,50 Yet quality of life has been the focus in few studies designed 
to investigate the effect of meditation or yoga. One study reported improvement in 
quality of life after a mindfulness meditation program in patients with diverse 
diseases; however, the absence of control group in the study made it difficult to 
assess the extent of improvement attributed to the meditation.30 Increased quality of 
life after yoga/relaxation treatment in elder heart failure patients was reported in a 
pilot study.31 Better quality of life in advanced AIDS patients who received a 
combination of Metta meditation and massage treatment was observed in a factorial 
randomized trial.32 Insufficient power was a drawback in both studies. Rigorous 
clinical research is required to strengthen the current understanding about the effect 
of yoga and meditation on quality of life. 
Sahaja Yoga Meditation is a simple method for individuals to achieve tranquility 
within.51 Beneficial effects of Sahaja Yoga Meditation in disease management have 
been documented in patients with epilepsy, 52 essential hypertension, 53 asthma, 54 
menopausal symptoms55 and attention deficit-hyperactivity disorder.56 The present 
study was designed to evaluate the effect of Sahaja Yoga Meditation on quality of life 
in individuals with heterogeneous health conditions. Quality of life and anxiety level 
were compared between patients who meditated and sought Sahaja Yoga 
Meditation treatment and non-meditating patients who sought conventional therapy.  
Differences in blood pressure were also evaluated in the subgroup of hypertensive 
patients.  
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6.3 STUDY DESIGN AND SETTING 
       This prospective observational cohort study was conducted in 2008 as an 
international public health project through the University of Pittsburgh Graduate 
School of Public Health. The study was approved by the Institutional Review Board 
in both the University of Pittsburgh and Mahatma Gandhi Mission Medical College 
and Hospital before implementation.  
       Two groups of patients were enrolled and followed. The common eligibility 
criterion in the study for both the meditation and control groups was men and non-
pregnant women between 18 and 65 years old who were willing to give written 
consent for being enrolled in the study. The meditation group was comprised of 
patients seeking care from the inpatient sector of the International Sahaja Yoga 
Research and Health Center, located at Navi Mumbai, India. The center was the first 
institute where treatment based on Sahaja Yoga Meditation was provided. Doctors 
were formally trained in Western medicine or Homeopathy and also meditated. 
Patients who sought treatments from the Sahaja Yoga Research and Health Center 
could have either major diseases or be seeking treatment for minor health issues.  
       The control group was comprised of patients receiving internal medicine care in 
the Mahatma Gandhi Mission (MGM) Medical College and Hospital located at Navi 
Mumbai, India. The MGM hospital provided primary to tertiary medical care for the 
community. Individuals who sought internal medicine care either had major diseases 
or were attending regular health checkups. Individuals were eligible for participating 
in the control group if they had not actively practiced meditation during the past 3 
months and were willing to forgo any practice of meditation for the duration of the 
study.  
 
6.3.1 Study Intervention 
       Treatment in the Sahaja Yoga Research and Health Center was daily meditation 
and application of Sahaja Yoga cleansing practices. The therapeutic effect of Sahaja 
Yoga Meditation was achieved in meditation, characterized by the state of mental 
silence where one could better introspect, address and resolve the distress caused 
by negative thoughts, emotions or behaviors. To facilitate the relaxation and mental 
silence (meditation), individuals could do simple exercises and cleansing practices, 
such as deep breathing for relieving the tension of the heart, foot-soaking with salt 
water for better circulation and muscle relaxation in the abdomen.53 In the Sahaja 
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Yoga Health Center, patients with diseases continued their standard medical 
treatment during their stay. The daily schedule for the inpatient sector in the Sahaja 
Yoga Health Center is described in table 1. From Monday to Saturday, patients 
started their day at five in the morning with individual meditation, followed by 
collective meditation. After breakfast, each patient met with his/her responsible 
physician and received treatment. In the afternoon, patients attended a meditation 
workshop for cleansing practices, and then collective meditation in the evening. A 
typical day ended around 10:30 at night. This daily schedule was designed to create 
a disciplined lifestyle where the patient’s attention and activities were focused on 
regaining health.     
 
6.3.2 Measurement 
Demographic and clinical characteristics were recorded at the time when 
participants registered to receive treatment. Quality of life and anxiety for all 
participants were measured both at study entry and the end of follow-up, which was 
at two weeks after treatment received or the time of discharge. 
Quality of life in this study was measured by the shorter version of the World 
Health Organization Quality of life instrument (WHOQOL-BREF) 19 and World Health 
Organization Quality of life—Spirituality, Religion and Personal Beliefs (WHOQOL-
SRPB).57 WHOQOL-BREF is a 26-item questionnaire evaluating quality of life from 4 
domains: physical health, psychological, social relationships, and 
environment/surroundings. WHOQOL-SRPB is a 32-item questionnaire measuring 
the impact of the spirituality, religion and personal beliefs on quality of life. The World 
Health Organization Quality of Life instruments were selected for its coverage of 
important quality of life aspects. Furthermore, its development and validation 
accounted for different cultural and value systems. The two weeks default time frame, 
with the flexibility to prolong or shorten for different study settings or patient 
populations, was appropriate for the present study.19 Both instruments were self-
administrated. If self-administration was difficult, an interviewer assisted 
administration by reading items to the participant. WHOQOL-BREF was summarized 
into 4 domain scores, and transformed to a 0-100 scale. WHOQOL-SRPB was 
calculated as a single domain score from 4-20. Higher score indicated better quality 
of life.  
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Anxiety was measured by the Clinical Anxiety Scale (CAS). The instrument was 
comprised of a 25-item self-report questionnaire measuring perceived anxiety level 
at the time of administration.58 The range of CAS scores was 0 to 100. A higher 
score indicated more perceived anxiety. 
       For self-reported hypertensive patients, blood pressure and pulse were 
measured both at baseline and the end of follow-up. Hypertensive patients rested in 
sitting position for five minutes before a trained staff measured their blood pressure 
with a calibrated sphygmomanometer. Pulse was measured at the wrist (radial 
artery). 
 
6.3.3 Analysis 
       Participants with both baseline and follow up assessments were included in the 
analysis. Baseline demographic, clinical, and quality of life characteristics in the two 
groups were summarized. Continuous variables were compared with Student's t-test 
and categorical variables with chi-square statistics.  
World Health Organization Quality of life instruments and clinical anxiety scale 
were scored according to the manuals.19,58,59 In the original field trial of WHOQOL-
SRPB, all missing values were treated as systematic missing and excluded from the 
analysis. In the current study, missing data management of WHOQOL-BREF was 
applied to WHOQOL-SRPB, such that if less than 30% items were missing within a 
domain for a patient; his/her mean domain score was used for imputing the missing 
value. The domain score of an individual was not calculated if more than 30% items 
were missing. 
       To compare the scores before and after the treatment within each group, Sign-
Rank tests were used for WHOQOL-BREF domain scores and paired T-test for other 
outcomes (WHOQOL-SRPB, CAS, blood pressure and pulse). To test between 
group differences at baseline, the end of follow-up and change from baseline to 
follow-up, Wilcoxon rank-sum tests and t-tests were used. The impact of meditation 
on follow-up quality of life measures, adjusted for essential covariates such as 
baseline quality of life values and social desirable response (SRDS) 60  were 
assessed by multivariate linear regression models. Years of hypertension and 
hypertension drugs use at baseline were included in models for follow-up blood 
pressure and pulse. Potential effect modification between meditation and patient 
characteristics on study outcomes were tested. If significant effect modification was 
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observed, the results were reported separately by levels of the characteristic. The 
two-sided alpha level for treatment effect and effect modification in hypertensive 
subgroup was set to 0.01. The analysis was performed using SAS 9.1. 
 
6.4 RESULTS 
From July to October, 2008, 70 of the 112 eligible patients admitted to the 
inpatient sector of the Sahaja Yoga Health Center consented to participate in the 
study and 67 completed follow-up. In the control group, 80 of the 120 eligible 
patients seeking care in the internal medicine clinic of the MGM hospital consented 
to participate in the study and 62 completed follow-up. 44 (70.0%) of the control 
patients received outpatient care. The mean follow-up time was 8.13 (±5.2) days for 
the meditation group and 14.25 (±2.6) days for controls. In the meditation group, the 
averaged years of practicing meditation was 7.4 (±4.9) years. 11 (16%) patients in 
the meditation group were from countries other than India, while all controls were 
Indians. The two groups were comparable in age, gender, marital, and working 
status (Table 2). The percentage of higher education was greater in the meditation 
group than controls. The control group had a higher physical activity level and lower 
BMI. At study entry, the prevalence of smoking and drinking were 16% and 13% in 
the control group, while none of the participants in the meditation group smoked nor 
consumed alcohol. The self-reported clinical history was similar in two groups, but 
the meditation group had higher prevalence of prior anxiety, depression, and 
gastrointestinal distress. One patient in the meditation group had a history of multiple 
scleroses, while two patients in the control group reported human immunodeficiency 
virus infection. At baseline, 13 (19.4%) patients in the meditation group and 28 
(45.2%) patients in the control group reported a history of hypertension required 
treatment. For patients with self-reported hypertension, the duration and 
management of hypertension were comparable.  
In the meditation group, after a week of Sahaja Yoga Meditation treatment, 
significant improvements were observed in all quality of life domains and clinical 
anxiety level (p<0.001, figure 1 and figure 2).  For hypertensive participants in the 
meditation group, significant improvements in systolic and diastolic blood pressure 
were observed.  Conversely, after an average two weeks of conventional treatment, 
the control group reported a significant decline in quality of life and greater anxiety 
 25
(p≤0.011).  For hypertensive participants in the control group, no improvement in 
blood pressure was observed after treatment received (Figure 1 and Figure 2).  
Between-group analyses showed that the meditation group had significantly 
higher average quality of life scores in all domains than controls at study entry.  After 
treatment, the meditation group experienced a greater improvement in all domains of 
quality of life (meditation group versus controls: physical: +7 versus 0; psychological: 
+13 versus 0; social: +6 versus 0; environmental: +7 versus 0; spiritual: +1.2 versus -
0.5 (0-20 scale), p <0.001) (Table 3). Baseline clinical anxiety scores were similar in 
two groups (p=0.74). After treatment, the improvement in anxiety was only observed 
in the meditation group, contrary to the higher levels of anxiety experienced by 
controls (between group difference p <0.001).  
For self-reported hypertensive patients, mean blood pressure and pulse were 
lower in the meditation group than controls at baseline. After treatment, the reduction 
in diastolic blood pressure was significantly greater for hypertensive patients in the 
meditation group than controls (-3.3 mmHg versus 1 mmHg, p=0.0043). There was a 
trend for greater reduction in mean systolic blood pressure in the meditation group 
than controls; the trend was not statistically significant (p=0.061), possibility due to 
more variability in systolic blood pressure change (a 13.2 mmHg standard deviation 
for change from baseline) in the meditation group. The between-group difference in 
pulse remained before and after treatment. At the end of follow-up, the mean pulse 
in meditation group was significantly lower compared to controls (73.7 versus 89.8, 
P<0.001).    
In multiple linear regression models, after adjustment for baseline value and 
potential confounders including age, social desirable answering pattern and self-
report illness, meditation remained the strongest independent covariate for 
improvement in quality of life and decrease in anxiety and blood pressure. Compared 
to controls, meditation was associated with a mean improvement of 15.7 units in 
physical, 21.7 units in psychological, 16.7 units in social, 13.2 units in environmental, 
and 2.3 units (by a 0 to 20 scale) in spiritual quality of life (p<0.001) (Table 4). 
Meditation treatment resulted in a significant reduction in clinical anxiety (-8.5 units, 
p<0.001) (Table 5).  
In hypertensive patients, meditation treatment was associated with a mean 12 
mmHg reduction in systolic blood pressure (p=0.018, borderline significant at an 
alpha level of 0.01). The quantitative effect of meditation on diastolic blood pressure 
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differed by diabetes status (p for effect modification=0.0053). In patients with both 
hypertension and type 2 diabetes, meditation treatment decreased diastolic blood 
pressure by 12.32 mmHg (p<0.001); the effect for hypertensive patients without 
diabetes was not as large but still significant (6.12 mmHg decrease, p <0.001). Pulse 
was similar in the meditation or control groups in the multivariate model.  
 
6.5 DISCUSSION 
        In the current study, an average of one week of Sahaja Yoga Meditation 
treatment was associated with significant improvement in perceived quality of life, 
anxiety reduction and blood pressure control.  The improvements among patients 
receiving meditation treatment were significantly greater than the changes observed 
in the control group of non-meditating patients.  
At baseline, individuals who practiced Sahaja Yoga Meditation had a higher level 
of quality of life in all domains than their non-meditating peers. In self-reported 
hypertensive patients, individuals who practiced Sahaja Yoga Meditation had a 
better blood pressure control compared to patients who received conventional 
treatment. 
  The five domains of the World Health Organization Quality of life inventory 
measure facets of perceived quality of life ranging from physiological health such as 
energy/fatigue, pain, and sleep; psychological self-esteem, memory and 
concentration; social relationships and support; accessibility and safety of the 
environment; to spiritual perceptions of wholeness, peace, hope and faith. At 
baseline, despite no dramatic between-group differences in demographics or clinical 
profile, the meditation group perceived a higher quality of life than controls. 
Individuals who sought Sahaja Yoga Meditation treatment had an average of seven-
year meditation practice. The baseline difference in perceived quality of life might be 
attributed to the prior meditation experience. On the other hand, when the change 
from baseline in quality of life was compared, taken into account the baseline 
difference in two groups, the meditation group experienced significant improvement 
while no change was observed in controls, suggesting Sahaja Yoga Meditation 
treatment was also associated with betterment over an extensive spectrum of quality 
of life. This association was supported by comparing the perceived anxiety in the 
meditation groups and controls. While similar anxiety level was observed in both 
groups at baseline, individuals who received Sahaja Yoga Meditation treatment had 
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significantly reduction in anxiety levels than their peers who received conventional 
therapy. 
In current study, there was a trend of 9.4 mmHg decrease in systolic blood 
pressure associated with Sahaja Yoga Meditation treatment. In current literature, a 
sustained 12-mm Hg decrease in systolic blood pressure for 10 years has been 
reported to prevent 1 death for every 11 patients treated.61 Sahaja Yoga Meditation 
was associated with greater decline in diastolic blood pressure then conventional 
treatment, and the rate of decline was greater for patients with both hypertension 
and type 2 diabetes, with an estimated 12 mmHg reduction in diastolic blood 
pressure. Hypertension is a major risk factor for cardiovascular disease and stroke, 
and it is estimated that a population-wide 2-mm Hg reduction in diastolic blood 
pressure could prevent 6% risk of coronary heart disease and 15% risk of stroke or 
transient ischemic attack.62  The decrease in blood pressure associated with Sahaja 
Yoga Meditation treatment could potentially lead to decrease in cardiovascular 
mortality and morbidity. 
The burden of hypertension continues to rise. In 2000, worldwide prevalence of 
hypertension was 26.4%translating to 972 million adults living with hypertension. 
Approximately one third (29.2%) of the adult population is estimated to have 
hypertension in year 2025, with an estimated population of 1.56 billion.63 In United 
States, 1999-2002 NHANES survey reported an estimate of 65 million adults living 
with hypertension.64, 65 High blood pressure was the primary cause or contributing 
cause of 11.31% deaths in United States in 2003. In 2006, the estimated direct and 
indirect coast of high blood pressure is 63.5 billion dollars.23 If further validation of 
the effectiveness of Sahaja Yoga Meditation on hypertension control are obtained, 
cost-effective intervention programs could result in significant lives saved and 
savings to individuals. 
 While particular causes of 96% of hypertensive cases remain unclear, research 
has proven that patients who are at an early stage with essential hypertension 
display an increase in sympathetic and a reduction in parasympathetic activity.66,67,68 
Increased overflow of sympathetic neurotransmitter (norepinephrine) is observed in 
kidneys and heart among patients with untreated essential hypertension.69 The high 
pulse observed in hypertensive patients corresponds to a high resting cardiac output 
and hyperkinetic circulation associated with the imbalanced autonomic nervous 
system.70  In this current study, pulse rates were lower in the meditation group than 
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controls at study entry and these lower levels remained in the duration of the study. 
The lower heart rate associated with meditation indicated a decreased sympathetic 
nervous system over-activity and increased parasympathetic nervous function in 
hypertensive patients, which might contribute to a better blood pressure control.  
    In addition, results from high-resolution electroencephalogram studies have 
shown that Sahaja Yoga Meditation was associated with an increased alpha and 
theta power and reduced complexity of EEG patterns over anterio-frontal and fronto-
central brain regions.71,72 It is well established that imbalance in autonomic activity 
causes cardiovascular diseases. 73 , 74  The autonomic imbalance is marked by 
disinhibition of sympathoexcitatory neural circuits, which are normally under tonic 
inhibitory control via the prefrontal cortex.75 By its potential of activating the limbic 
area for better tonic control for autonomic nervous system, Sahaja Yoga Meditation 
may have the beneficial effect of decreasing the occurrence of psychosomatic 
disorders. 
The study was subject to several limitations. As an observational cohort study, 
participants were self-selecting into the study groups. At study entry, the meditation 
group had an averaged 7 years of meditation, and may influence their perceptions of 
quality of life. Although the results were adjusted for baseline quality of life values, 
duration of meditation and other confounders, between group differences could not 
be fully controlled. The study evaluated the effect of Sahaja Yoga Meditation within 
the specific setting of the health center, where patients received a regimented 
schedule on meditation and treatment. As a result, the effects observed in the study 
were attributable to the combination of meditation and life in the health center.  A 
potential placebo effect might be of concern, in which the observed improvement 
was possibly due to having the regimen of treatment practices. However, at baseline, 
clinical history and chronic disease severity was comparable in both groups. The fact 
that control groups reported deterioration in outcomes while meditation group 
reported improvements suggest a benefit beyond placebo effect. Perceived quality of 
life is best measured by self-report, and the study controlled the effect of high 
respondent by adjusting the aptitude of reporting socially desirable answers. The 
sample size of hypertensive subgroup is small; nevertheless, within or between 
group differences in blood pressure were sufficient to result in reasonable power 
(The post hoc estimated statistical power of observing the 9.41 mmHg decline in 
systolic blood pressure in the study was 62%).  
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A common challenge in behavioral studies is the recruitment and retention of the 
participants. This challenge did not hamper the current study, and the retention rate 
was very high. Since the study period was brief (two weeks commitment from each 
subject), the burden of participation was minimized.  
  
6.6 CONCLUSION 
The current study reports that patients who received Sahaja Yoga Meditation 
treatment in conjugation with conventional treatment benefited in diseases 
management and in perceived quality of life. Further investigation is recommended 
for the associations between Sahaja Yoga Meditation and blood pressure reduction, 
especially for patients with both hypertension and type 2 diabetes. Future clinical 
studies with a refined experimental design on the effectiveness of Sahaja Yoga 
Meditation for managing chronic conditions, such as prehypertension, hypertension 
and type 2 diabetes are recommended.  
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6.7 TABLES AND FIGURES 
 
Table 1: Daily schedule of at the Sahaja Yoga Research and Health Center for 
inpatient patient 
 
05:00 Wake up, Individual meditation 
8:30-9:30  Collective meditation 
10:30-14:00 Doctor Consultation  
16:30-18:30 Collective workshop (for example, foot-soaking) 
19:00-20:30 Collective meditation 
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Table 2: Demographic and clinical profile of study groups at study entry 
 Meditation (N=67) Controls (n=62) P value 
Age, mean (SD) 40.53 (11.9) 42.01 (15.5) 0.6 
Female, n (%) 35 (52.2) 29 (46.8) 0.49 
Marital status, n (%)   0.2 
Never married 17 (25.4) 10 (16.1)  
Married 46 (68.7) 50 (80.6)  
Widowed 1 (1.5) 2 (3.2)  
Divorced/separated 3 (4.5) 0 (0)  
Education level, n (%)   <0.001 
< High school 0 (0) 16 (25.8)  
  High school graduate or some   
college 19 (28.4) 17 (27.4)  
Bachelor degree 30 (44.8) 22 (35.5)  
Graduate degree 18 (26.9) 7 (11.3)  
Work status, n (%)   0.47 
Working full time 36 (53.7) 35 (56.5)  
Working part-time/homemaker 21 (31.3) 22 (35.5)  
Other 10 (14.9) 5 (8.1)  
Activity level, n (%)   <0.001 
Sedentary 8 (12.1) 1 (1.6)  
Mild 21 (31.8) 5 (8.1)  
Moderate 31 (47.0) 32 (51.6)  
Strenuous 6 (9.1) 24 (38.7)  
BMI, mean (SD) 23.82 (3.5) 21.86 (4.5) 0.0069 
Ever smoking, n (%) 17 (25.4) 17 (27.4) 0.79 
Current smoke, n (%) 0 (0) 10 (16.1) <0.001 
Alcohol consumption during the 
past year, n (%) 0 (0) 8 (12.9) 0.0024 
History of heart disease (including 
angina), n (%) 4 (6.0) 7 (11.3) 0.28 
History of type 2 diabetes, n (%) 10 (14.9) 9 (14.5) 0.95 
History of asthma, n (%) 2 (3.0) 3 (4.8) 0.59 
History of anxiety or depression, n 
(%) 10 (14.9) 2 (3.2) 0.022 
History of gastrointestinal distress, 
n (%) 18 (26.9) 6 (9.7) 0.012 
History of hypertension, n (%) 13 (19.4) 28 (45.2) 0.0017 
Self-reported hypertension patients (n=41) 
# hypertension drugs taken, 
median (Q1,Q3)  1 (1,2) 2 (1,2) 0.26 
Hypertensive years (n=41), mean, 
SD 5.62 (3.4) 3.93 (5.0) 0.28 
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Table 3: Outcome comparisons between meditation (n=70) and control groups (n=62) at baseline and follow-up  
WHOQOL-BREF Physical, 
median (Q1,Q3) 
WHOQOL-BREF Psychological, 
median (Q1,Q3) 
WHOQOL-BREF Social, 
median (Q1,Q3) 
 
Meditation Control P Meditation Control P Meditation Control P 
Baseline 69 (56, 75) 56 (44, 63) <0.001 63 (44, 69) 56 (44, 56) 0.004 75 (56, 75) 56 (50, 75) <0.001
Follow-up 75 (69, 81) 53 (44, 56) <0.001 75 (69, 81) 53 (44, 56) <0.001 75 (75, 81) 56 (50, 56) <0.001
Difference 7 (0, 19) 0 (-6, 0) <0.001 13 (6, 25) 0 (-6, 0) <0.001 6 (0, 13) 0 (-13, 0) <0.001
WHOQOL-BREF  Environmental, 
median (Q1,Q3) 
WHOQOL-SRPB, 
mean (SD) 
Clinical Anxiety Level, 
mean (SD) 
 
Meditation Control P Meditation Control P Meditation Control P 
Baseline 69 (56, 75) 56 (44, 63) <0.001 15.38 (2.3) 12.44 (1.8) <0.001 22.22 (13.8) 21.53 (9.4) 0.74 
Follow-up 75 (69, 88) 56 (44, 63) <0.001 16.57 (2.0) 11.98 (1.7) <0.001 15.18 (10.7) 23.19 (7.7) <0.001
Difference 7 (0, 19) 0 (0, 0) <0.001 1.18 (1.7) -0.47 (0.6) <0.001 -7.07 (13.1) 1.66 (3.9) <0.001
Hypertensive subgroup comparisons (n=41) 
Systolic blood pressure, 
mean (SD) 
Diastolic blood pressure, 
mean (SD) 
Pulse, 
mean (SD) 
 
Meditation Control P Meditation Control P Meditation Control P 
Baseline 134.26 
(17.8) 
151.19 
(15.3) 
0.0042 83.58 (9.4) 93.38 (7.1) <0.001 68.20 (11.5) 85.81 (6.9) <0.001
Follow-up 123.19 
(18.9) 
150.32 
(13.0) 
<0.001 78.21 (7.2) 94.39 (4.9) <0.001 73.70 (10.6) 89.76 (7.0) <0.001
Difference -9.41 (13.2) -0.87 (5.1) 0.061 -3.33 (4.5) 1.01 (3.7) 0.0043 3.28 (8.5) 3.67 (5.3) 0.87 
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Figure 1 Baseline versus follow-up for quality of life measures within meditation and control groups (mean±1.96 SE). 
Meditation 
Controls 
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Figure 2 Baseline versus follow-up for clinical anxiety, blood pressure, and pulse within meditation and control groups 
(mean±1.96 SE) 
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Table 4 The effect of meditation on quality of life, adjusted for demographic and clinical variables (n=129) 
WHOQOL-BREF  
Physical 
Domain (0-100) 
Psychological 
domain (0-100) 
Social Domain 
(0-100)  
Environmental domain 
(0-100) 
WHOQOL 
SRPB (0-20) 
R square 0.7339 0.7232 0.7358 0.8076 0.8741 
Parameters Est. P Est. P Est. P Est. P Est. P 
Meditation (reference: 
controls) 
15.7 <0.001 21.66 <0.001 16.66 <0.001 13.22 <0.001 2.29 <0.001
Baseline value 0.51 <0.001 0.45 <0.001 0.48 <0.001 0.71 <0.001 0.71 <0.001
SDRS1 2.60 0.004   2.11 0.03 2.96 <0.001 0.29 0.013 
Age -0.17 0.003     -0.10 0.032 -0.02 0.007 
Indian race   5.77 0.038       
Education level 
(reference: high school or 
less) 
     0.023     
High school graduate 
or some college 
    -0.28      
Bachelor Degree     2.04      
Graduate Degree     6.97      
Self report history of 
gastrointestinal disease 
    -5.78 0.007     
Ever smoking         -0.47 0.034 
1Social desirable Response measure 
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Table 5 The effect of meditation on anxiety level and blood pressure, adjusted for demographic and clinical variables 
 Clinical Anxiety
1 
(n=129) 
Systolic blood  
Pressure (n=41)2 
Diastolic blood  
Pressure2 (n=41) Pulse (n=41) 
R square 0.5539 0.8484 0.9326 0.7454 
Parameters Est. P Est. P Est. P Est. P 
Meditation (reference: controls) -8.46 <0.001 -12.01 0.018   -5.42 0.081 
Meditation versus controls in  
hypertensive patients with diabetes      -12.32 <0.001   
Meditation versus controls in  
hypertensive patients without diabetes     -6.12 <0.001   
Baseline value 0.48 <0.001 0.83 <0.001 0.59 <0.001 0.70 <0.001
Self reported history of type 2 diabetes     -0.32 0.77   
1 Model for clinical anxiety is also adjusted for physical activity and marital status. 
2 P value for interaction between meditation and self reported history of type 2 diabetes on diastolic blood pressure: 0.0053 
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7. Paper two: The effect of age on clinical and quality of life outcomes in the 
Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial.  
 
(The abstract was presented at the AHA 50th cardiovascular disease epidemiology and 
prevention conference in 2010.) 
 
7.1 ABSTRACT 
 
Background: Coronary revascularization in elderly patients has increased dramatically 
in the past decade. Previous clinical trials have reported conflicting results about the 
effectiveness of revascularization in older populations.  
Methods:  In BARI 2D, 2368 patients with stable ischemic heart disease and type 2 
diabetes were randomized to 1) prompt revascularization versus medical therapy and 2) 
insulin sensitization versus insulin provision. Patients were followed for an average of 
5.3 years.  The primary outcomes were death and the composite of death, myocardial 
infarction (MI), and stroke. Secondary endpoints included health status. Cox regression 
and mixed models were used to investigate the effect of age on study outcomes and 
randomized treatment effectiveness. 
Results:  Older age was significantly associated with higher rates of death (p<0.001) 
and death/MI/stroke (p<0.001); however, the effect of prompt revascularization versus 
medical therapy on cardiovascular events did not vary by age.  Compared to younger 
patients, older patients had lower physical function but higher energy and self-rated 
health, and less health distress at baseline. After an initial improvement in health status 
during the first year, older patients experienced an accelerated decline in health status 
over subsequent years (effect modification for age and follow-up time: p <0.01).  
Conclusion:  Among patients with diabetes and coronary disease, older patients were 
at greater risk for cardiovascular events but had similar outcomes with an invasive or 
conservative cardiac treatment strategy. Older patients experienced an accelerated 
decline in health status than their younger peers. 
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7.2 INTRODUCTION 
        Although use of coronary revascularization has increased rapidly among older 
adults during the past decade; 76  its effectiveness in this population has remained 
controversial. Concerns exist about procedural mortality risk and complications as well 
as long-term effectiveness in the elderly population.77 A recent meta-analysis reported 
that coronary artery bypass grafting (CABG) resulted in a better survival than 
percutaneous coronary interventions (PCI) in older patients with multi-vessel coronary 
disease.78 However, randomized clinical trials comparing revascularization to medical 
therapy in older patient subgroups, did not find any significant survival advantage 
associated with one or the other treatment approach.79,80,81 Another area of uncertainty 
is the effectiveness of medical therapy and the optimal clinical approach to managing 
common chronic co-morbidities in the elderly such as hypertension 82  and type 2 
diabetes.83 
The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) is a 
randomized clinical trial that evaluated the treatment strategies for patients with stable 
ischemic heart disease and type 2 diabetes. Within the framework of BARI 2D, the 
current study hypothesized 1) older age is associated with higher incidence rates of 
adverse clinical outcomes, 2) the effectiveness of randomized treatment strategies for 
ischemic heart disease and for glycemic control differed by age, and 3) the treatment 
and the time effect on health status change over four years of follow-up differed by age.  
 
7.3 METHODS 
7.3.1 Study Settings 
The study design and primary outcomes of BARI 2D trial have been published 
previously.43, 48 In brief, 2,368 patients with stable ischemic heart disease and type 2 
diabetes were randomized to receive one of the two randomized ischemia treatments—
prompt revascularization (REV) or medical therapy with a delayed revascularization 
when necessary (MED), and simultaneously randomized to one of the two glycemic 
treatments— insulin sensitizing (IS) or insulin providing (IP) drug to achieve a serum 
Hemoglobin A1c level of less than 7.0%. Before randomization, each consented patient 
was evaluated by a responsible physician to determine which revascularization strategy 
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(CABG or PCI) was appropriate based on the extent of heart disease. In BARI 2D, the 
intended revascularization strategy was an important variable to define patient 
subgroups. The recruitment of the trial was between January 1, 2001 and March 31, 
2005. The trial follow-up ended November 30, 2008 and the 2,368 patients were 
followed for an average of 5.3 years.  
 
7.3.2 Outcomes 
Clinical Endpoints 
The clinical outcomes of interest included death from all causes, a composite of 
death, myocardial infarction (MI) and stroke, cardiac death and a subsequent procedure. 
In the prompt revascularization group, the initial procedure was carried out within four 
weeks after randomization. Vital status was obtained from clinical visits and regular 
contacts made by each clinical site, supplemented with a national database search for 
patients with unknown vital status after the end of follow-up. Diagnosis of MI was based 
on serum cardiac biomarkers and core electrocardiography laboratory assessments. 
Stroke and cause of death were adjudicated by an independent committee.   
Repeated Health Status Measures 
        The health status was assessed by four instruments—the Duke Activity Status 
Index (DASI),20 RAND Medical Outcome Study Energy/fatigue and health distress 
scales, and self-rated health. Health status was assessed at baseline and during each 
annual follow-up visit. The score ranged from 0-58.2 for DASI, 0-100 for the 
Energy/fatigue. Self-rated health was measured in a five-category Likert scale and can 
be scored as a 0-100 continuous score.46 A higher score indicated better health status. 
Conversely, the score of health distress ranges from 0-100 and a higher score indicated 
worse perceived distress.  
 
7.3.3 Statistical Analysis  
Baseline demographic, clinical, and health status profile were summarized by five-
year age groups (<55, 55-60, 60-65, 65-70, ≥70). Continuous variables were compared 
with Student's t-test and categorical variables with chi-square statistics. 
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For the survival analysis of each clinical outcome, data were censored at five year 
follow-up. Kaplan–Meier survival curves with Log-rank test statistics were used to 
investigate the difference in survival experiences by baseline age groups. Survival 
curves by randomized treatment assignments were compared within each subgroup 
defined by five year age category to examine whether the effect of randomized 
treatment on clinical outcomes differed by baseline age groups. The hazard ratio of 
adverse clinical outcomes associated with older age was estimated by Cox proportional-
hazards regression models, where baseline age was incorporated as a continuous 
variable, centered at its mean. The proportional hazard assumption of Cox regression 
models was tested by the significance of interaction between key covariates and follow-
up time. If non-proportional hazards were observed, the estimates of centered age on 
clinical outcomes was obtained by stratification, in which separate partial likelihood 
functions were constructed according to different levels of the variable where non-
proportional hazards occurred, the model then find the solution that maximized the 
multiplication of the likelihood functions.    
For the longitudinal analysis of repeated health status measures, data were 
truncated at year four, due to an increasing proportion of patients not having year five 
clinical visit due to late enrollment. Only patients with at least one follow-up health 
status measure were included in the analysis. The trend in health status over time was 
first displayed by five-year baseline age groups, and analyzed with linear mixed models 
to account for the correlation in repeated measures. To investigate the difference over 
time by age, the data were parameterized with baseline health status as the first 
repeated measure. Categorical variables for time and age were used in the model to 
compare health status at each follow-up visit to the baseline. Alternatively, to investigate 
the treatment effect by age, the data were re-parameterized with year 1 health status as 
the first repeated measure and baseline as a covariate; Follow-up time and baseline 
age were incorporated as continuous variables in the mixed model. The treatment effect 
on health status was also assessed in five-year baseline age subgroups.    
To control for potential confounders in the association between age and study 
outcomes, multivariate models were constructed adjusting for potential confounders at 
baseline: CABG stratum, sex, smoking, body mass index (BMI), angina severity, insulin 
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use, history of hypertension, congestive heart failure, myocardial infarction, stroke, non-
coronary artery disease, and clinical neuropathy. Effect modification between baseline 
age and randomized treatment, intended revascularization methods and follow-up time 
were tested in multivariate models. 
Clinical sites were controlled as random effects in mixed models, where as sites 
were managed in the Cox models by incorporating a categorical variable for geographic 
region. Treatment effect was analyzed based on the intention-to-treat principle. In 
models evaluating prompt revascularization versus medical therapy, two variables—the 
intended revascularization method and baseline angina severity (not balanced between 
randomized ischemic treatment groups), were controlled in the analysis. A two-sided 
alpha level for age effect modification and subgroup analyses was set to 0.01 to control 
for multiple comparisons. 
 The assumption of a linear association between centered baseline age and study 
outcomes was examined by adding a quadratic age variable and tested its significance. 
Missing baseline covariates were managed by mean values imputation, calculated 
separately by the intended revascularization method. In health status analysis, missing 
outcomes were identified if a patient did not provide health status data at annual follow-
up visit, with an exception of administrative censoring. Under the missing at random 
assumption in mixed model, missing outcomes were not imputed. To account for 
potential missing not at random, a categorical variable for three missing patterns: 
completers (no missing), noncompliance and dropouts was added as a covariate in the 
models.27 To examine the effect of excluding patients with no follow-up health status 
measure, missing health status outcomes was imputed using multiple imputation for all 
BARI 2D patients, and parameter estimates from the imputed data were compared to 
those from the original data.  All analyses were performed using SAS 9.0.   
 
7.4 RESULTS   
Randomized treatment was balanced among baseline age groups. A greater 
proportion of elderly patients (age ≥ 60) had coronary disease more suitable for bypass 
surgery than PCI. At baseline, younger patients had larger BMI and lower systolic blood 
pressure but had higher diastolic blood pressure than older patients, while patients 
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more than 60 years old had higher prevalence of prior cardiovascular complications.  
For diabetes control, the youngest patients had highest mean serum HbA1c of 8.1% 
while the oldest patients entered the trial with a mean HbA1c of 7.1%, which was close 
to the glycemic control target in BARI 2D. The highest percentage of baseline insulin 
use was in the 55-60 age group (30.8%). At baseline, younger patients had the higher 
average DASI scores but lower energy, more health distress and rated their health 
worse than older patients.  
All 2,368 BARI 2D patients were included in the survival analysis.  One year 
increase in age at study entry was significantly associated with higher risk of adverse 
events including death (hazard ratio: 1.06, p<0.001), death/MI/stroke (hazard ratio: 1.03, 
p<0.001), cardiac death (hazard ratio: 1.03, p=0.0028) and a lower risk of subsequent 
revascularization (hazard ratio: 0.99, p=0.0032). Baseline age did not modify the effect 
of ischemic treatment strategy at 5-year follow up (interaction p values for age and 
revascularization: 0.97 for death; 0.71 for death/MI/stroke; 0.99 for cardiac death and 
0.19 for subsequent procedure). Survival rates were similar in prompt revascularization 
and medical therapy groups, except for patients aged between 65 and 70 at baseline, 
where medical therapy resulted in better survival rate than prompt revascularization 
(81.1% for REV and 89.7% for MED), with a borderline significance of 0.012 (Table 2, 
Figure 1).  
Insulin sensitizing and insulin providing strategies resulted in similar survival in all 
age groups (interaction p value for age and insulin sensitizing: 0.44 for death; 0.67 for 
death/MI/stroke; 0.85 for cardiac death and 0.72 for subsequent procedure) (Table 2). 
Baseline age did not modify the effect of glycemic treatment on clinical outcomes at 
five-year follow up. Since the hazard rate for prompt revascularization versus medical 
therapy was not constant throughout follow-up time for mortality outcomes, therefore 
multivariate Cox regression models estimating the effect of age were stratified by 
cardiac treatment strategies. After controlling for potential confounders, older age was 
significantly associated with higher rates of death, death/MI/stroke, cardiac death and 
lower rate of subsequent revascularization (Table 3). 
A total of 2,163 patients were included in the longitudinal analysis for health status. 
Health status improved significantly at the first year compared to baseline for all age 
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groups, yet the pattern over time differed. Younger patients had higher baseline DASI 
scores, and the improvement from baseline was greater and sustained longer (Figure 2). 
Conversely, for patient more than 70 years old at baseline, mean DASI scores after 
year three were significantly lower than at baseline (Table 3). For the Energy 
questionnaire, younger patients started with low baseline scores but experienced the 
largest improvement during the first year of follow-up, and the mean Energy score 
continued to improve through year four for the youngest age group. The trends in Health 
distress and self-rated health were similar to that in Energy.  The age difference in DASI 
increased over follow-up, while it diminished for other health status measures (Figure 2).  
Over four follow-up years, the effect of randomized treatment on health status did 
not differ by baseline age (Figure 3 and Figure 4). Subgroup analysis showed that 
prompt revascularization compared to medical therapy resulted in a mean 2.19 point 
increase in DASI score (p=0.0090) and a mean 4.31 point higher in Energy scores 
(p=0.0016) in the 60-65 baseline age group (Figure 3). Randomized glycemic treatment 
resulted in similar change in health status in all age groups (Figure 4).  
In multivariable analysis, after controlling for confounders, a one year increase in 
baseline age was significantly associated with a 0.13 unit worsening in DASI score 
(p<0.001) at the one year follow-up. The DASI scores declined over follow-up (-0.66 per 
year, p<0.001) and older patients experienced an accelerated decline during follow-up 
(interaction p-value for baseline age and follow-up time: 0.0015) (Table 5, Figure 5). 
Older age was associated with higher Energy (p=0.045) and lower Health distress 
(p<0.001); however, as follow-up time increased, older patients experienced a steeper 
decline in Energy and accelerated increase in health distress (interaction p <0.001). 
Conversely, baseline age was not associated with change in self-rated health after 
adjusting for confounders (p=0.23). 
In sensitivity analysis, the estimates of association between age and DASI score, 
health distress and self-rated health in the imputed data were similar to the original 
(Table 6). Although baseline age was not significantly associated with Energy in the 
imputed data, the effect modification of older age on Energy decline over time remained 
similar (Table 6, Figure 6).  
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7.5 DISCUSSION  
Among patients with stable ischemic heart disease and type 2 diabetes, older 
patients had higher long term event rates for death and major cardiovascular events, 
however, the comparative treatment effect of prompt revascularization versus medical 
therapy, and insulin providing versus insulin sensitizing on clinical endpoints or health 
status outcomes did not vary by age. In health status outcomes, after initial 
improvements, older patients experienced an accelerated decline in health status than 
their younger peers. The steeper decline was most evident for functional capacity. 
Patients who were older than 70 perceived better Energy, less health distress and rated 
their health better at the end of the four year follow-up than at baseline, but, their 
functional capacity was significantly worse than before study enrollment. 
Our results were consistent with previous clinical trials evaluating effectiveness of 
revascularization versus medical therapy that did not find a significant interaction 
between age and treatment effectiveness for clinical outcomes. In the COURAGE trial, 
where 2,287 patients with stable coronary artery disease were randomized to receive 
either PCI or medical therapy, the effect of revascularization did not differ by age.78 The 
CASS study reported similar effect of bypass surgery versus medical therapy on 
survival in various age subgroups of patients with stable angina.82 Concurrent to CASS, 
the European Coronary Surgery Study with similar study design and patient population 
reported a trend of greater survival benefit for bypass surgery over medical therapy in 
patients aged above 53 at baseline, but the effect modification between age and 
treatment was not statistically significant.84  
In clinical trials for type 2 diabetes, the PROACTIVE trial randomized 5,238 patients 
with type 2 diabetes and macrovascular diseases to either receive pioglitazone or 
placebo for diabetes treatment.85 The MICRO-HOPE trial compared hypertension drug 
(ramipril) versus placebo on diabetic complication or cardiovascular disease in type 2 
diabetic patients.86 In both studies, the effect of active treatment versus placebo on 
death and cardiovascular complications did not differ by age.  
The association between age and health status outcomes was assessed in few 
randomized trials comparing revascularization versus medical therapy. In RITA-2 study, 
older patients had similar physical functioning but significantly higher vitality and general 
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health scores then younger patients and the effect of age was independent of 
randomized treatment (PCI or medical therapy).38 In the original BARI trial, which was 
aimed to investigate the effectiveness of bypass surgery versus angioplasty, older age 
was independently associated with a decline in DASI scores and improvement in mental 
health.34 The results of the current study are in agreement with the previous findings in 
the original BARI trial.  
To determine which ischemic treatment strategy was more appropriate for the 
elderly, the TIME trial compared revascularization versus medical therapy in 305 
patients who were more than 75 years old and had chronic ischemic diseases. The 
primary outcome was health-related quality of life. At six months of follow-up, the 
improvement in symptom relief and health-related quality of life was greater in 
revascularization than medical therapy, while no difference was observed in survival 
without MI by randomized treatment. 87  In subgroup analysis of the current study, 
revascularization, compared to medical therapy, did not result in a favorable 
improvement in health status for patients older than 70 years. The difference may be 
the longer follow-up time in BARI 2D for observing the association between age and 
health status change over time. 
Limitations 
BARI 2D included patients with moderate ischemic heart disease and type 2 
diabetes suitable for either treatment strategies in ischemia management and glycemia 
control. Consequently, the study population may not fully represent all patients with 
heart disease and type 2 diabetes. For example, elder patients in BARI 2D had 
relatively good diabetes control at baseline; it is possible that the longevity due to good 
diabetes control enabled them to participate in the trial. In the longitudinal analysis, the 
association of age and health status was limited to patients with health status 
information available at the minimum of one follow-up. The lack of health status 
information is some patients may be a concern. However, when we compare the results 
to those in sensitivity analysis where missing health status data were imputed using 
multiple imputation method, the associations between age and DASI scores, health 
distress and self-rated health were similar in the original and imputed data. The effect 
modification was more sensitive to the missing data, as in the imputed data, the older 
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age and faster decline in DASI during follow-up became insignificant. However, the 
effect modification remained significant for Energy and Health distress. 
 
7.6 CONCLUSION 
 In the current study, for patients with stable heart disease and type 2 diabetes, age 
did not modify treatment effectiveness of prompt revascularization versus medical 
therapy, or insulin sensitizing versus insulin providing drug for clinical and health status 
outcomes. After initial improvement in health status, older patients experienced an 
accelerated decline in health status over time compared with their younger peers. The 
age-accelerated decline was most prominent for functional capacity.  
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7.7 TABLES AND FIGURES 
 
Table 1: Baseline characteristics by baseline 5-year age groups 
Age groups <55 55-60 60-65 65-70 >=70 
N 499 440 500 415 514 
p 
Trial and demographic characteristics 
CABG Strata, % 26.7 27 36.2 38.6 33.1 <0.001 
Prompt revascularization, % 49.7 52.5 47.4 51.1 48.2 0.53 
Insulin Sensitizing, % 51.5 52 48.2 47.2 50.6 0.53 
Male, % 69.9 71.1 73.8 72 65.4 0.046 
RACE, % 
  White 57.7 59.5 68.8 72.3 71.2 <0.001 
  Black 20.4 19.1 15.6 13.3 15.4  
  Hispanic 15.2 16.6 10.6 11.3 9.3  
  Other 6.6 4.8 5 3.1 4.1  
Geographic Region, % 
  USA 60.7 64.1 60 60.5 70.6 0.0019 
  Canada 15.2 15.9 15.4 13.5 14.4  
  Mexico 4.6 4.3 4 3.4 1.8  
  Brazil 17.6 12 16.8 19 10.1  
  Czech Republic/Austria 1.8 3.6 3.8 3.6 3.1  
Current cigarette smoker, % 23 16.9 13 7.2 2.3 <0.001 
Former cigarette smoker, % 47.1 53.1 55.4 58 59 0.0014 
BMI, mean 32.8 32.5 32.0 30.8 30.6 <0.001 
Sitting systolic BP, mean 127.7 129.4 132.6 134.1 134.8 <0.001 
Sitting diastolic BP, mean 77.7 75.7 74.9 74.5 70.0 <0.001 
Cardiac characteristics 
History of MI, % 36.1 33.8 31.6 28.4 30.1 0.1 
Angina Category, % 
  None/Angina equivalent only 31.3 36 42.2 41.7 45.3 <0.001 
  Stable CCS1/CCS2 46.4 42.8 39 43.4 41.2  
  Stable CCS3/CCS4/Unstable 22.4 21.2 18.8 14.9 13.4  
# of vessels with region (>=50%), % 
  0 4 4.3 2.6 3.4 3.7 0.48 
  1 31.9 32.1 29.9 25.8 29.2  
  2 35.3 36.9 34.7 37.4 35.6  
  3 28.9 26.7 32.9 33.5 31.5  
Site: LVEF < 50%, % 16.4 17.4 19.5 15.9 17.8 0.66 
Hypertension requiring tx, % 78.7 80.1 85.3 84.3 84.2 0.025 
History of CHF req tx, % 4.5 5.3 7.8 7.3 8.2 0.073 
Cerebrovascular accident TIA, % 5.9 6.8 10 13.5 12.7 <0.001 
Non-coronary artery disease, % 17.5 22 27.2 25.5 26.5 0.0014 
COPD, % 2.6 5.7 6.4 5.1 5.5 0.071 
Prior PCI, % 19.7 20 17.6 21.2 19.8 0.73 
Prior CABG, % 4.8 5.7 8 5.3 8 0.11 
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Table 1 continues:  
 
Age groups <55 55-60 60-65 65-70 >=70 p 
N 499 440 500 415 514  
Diabetic characteristics 
Duration of DM, mean 7.7 9.3 10.9 11.7 12.6 <0.001 
HbA1c %: Core augmented with 
site estimate, mean 8.1 7.9 7.7 7.5 7.1 <0.001 
Currently taking insulin, % 26.7 30.8 29.6 26.6 25.9 0.38 
History of hypoglycemic episode, 
% 18.1 24 22.3 24.6 25.3 0.059 
Neuropathy: clinical MNSI > 2, % 43.1 46.4 51.7 53 57 <0.001 
Laser tx for diabetic 
retinopathy/macular edema, % 2.4 1.6 4.2 3.4 3.6 0.16 
Legally blind, % 1 0.2 0.6 0.2 0.4 0.43 
Lower extremity amputation, % 1 1.1 1 1.5 1.6 0.89 
Quality of life      
DASI (0-58.2), mean 20.5 18.8 19.1 19.4 17.0 0.0017 
Energy score (0-100), mean 50.4 46.7 50.5 56.2 53.2 <0.001 
Health distress score (0-100), 
mean 48.1 46.3 39.3 35.3 33.4 <0.001 
Self rated health category, mean 36.1 33.2 39.4 40.6 43.3 <0.001 
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Table 2: Five-year survival and free of death/MI/Stroke rate by baseline 5-year age groups and randomized treatment. 
 
Ischemic Randomized Treatment Glycemic Randomized Treatment 
Overall CABG PCI Age groups Overall 
REV MED REV MED REV MED 
IS IP 
Five year survival probability      
<55 94.1 94.9 93.4 94.0 89.8 95.2 94.6 95.5 92.6 
[55,60) 89.8 91.7 87.8 93.8 78.2 91.0 91.0 87.7 92.1 
[60,65) 90.8 89.5 91.9 89.6 88.5 89.5 93.6 91.7 90.0 
[65,70) 85.3 81.1 89.7 76.7 89.1 83.3 90.1 84.9 85.8 
>=70 80.3 83.5 77.4 78.8 72.5 85.8 79.8 80.9 79.6 
 
Five year free of death/MI/stroke rate    
<55 83.6 82.4 84.7 81.7 84.5 82.4 85.0 86.7 80.3 
[55,60) 77.1 78.0 76.3 84.0 60.0 75.6 82.1 77.4 76.7 
[60,65) 79.2 79.9 78.6 78.7 76.8 80.6 79.9 80.9 77.8 
[65,70) 75.4 72.7 78.1 69.5 72.5 74.2 82.0 75.4 75.4 
>=70 67.6 72.3 63.4 73.6 56.3 71.7 67.0 68.0 67.1 
 
Five year free of cardiac death rate    
<55 96.4 96.4 96.4 97.2 94.8 96.0 97.0 97.2 95.5 
[55,60) 93.4 95.1 91.5 95.3 84.2 95.1 94.1 91.8 95.1 
[60,65) 95.3 93.7 96.7 91.9 93.5 94.7 98.2 96.6 94.1 
[65,70) 92.1 90.2 94.2 85.2 91.5 93.0 96.1 91.2 93.0 
>=70 93.0 94.1 91.9 91.0 88.7 95.6 93.4 93.8 92.0 
 
Five year free of subsequent procedure 
rate    
<55 63.9 69.5 58.4 90.8 62.3 61.1 57.0 64.5 63.3 
[55,60) 61.4 74.8 46.1 80.8 49.4 72.4 44.8 59.7 63.1 
[60,65) 70.7 79.5 62.9 91.8 63.2 72.9 62.6 75.3 66.3 
[65,70) 71.3 80.0 62.8 94.5 70.5 71.8 57.7 73.9 69.0 
>=70 68.6 80.3 57.6 97.2 52.7 72.9 60.3 69.9 67.2 
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Figure 1 continues.  
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Figure 1: 5-year survival, REV versus MED, by baseline age categories. P value for the interaction between 
centered baseline age (continuous) and revascularization: 0.97 
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Table 3. Multivariable regression models for clinical outcomes during BARI 2D follow-up. 
 
Death Death/MI/Stroke Cardiac death Subsequent procedureVariable 
Hazard Ratio p Hazard Ratio p Hazard Ratio p Hazard Ratio p 
Age per 1 year increase 1.06 <0.001 1.03 <0.001 1.03 0.0088 0.99 0.024 
REV versus MED in CABG stratum 0.16 <0.001 
REV versus MED in PCI stratum 0.62 <0.001 
IS versus IP 1.03 0.83 1.15 0.12 1.04 0.83 1.12 0.14 
CABG versus PCI stratum 1.40 0.010 1.30 0.011 1.89 0.0012 1.20 0.095 
Stable CCS1/CCS2  0.92 0.57 1.04 0.69 0.91 0.63 1.33 0.0016 
CCS3/4 or unstable  0.96 0.83 1.15 0.29 0.96 0.87 1.84 <0.001 
Currently taking insulin 1.37 0.021 1.47 <0.001 1.47 0.047 1.16 0.078 
Male 1.28 0.084 0.97 0.73 1.08 0.70 0.93 0.41 
BMI 1.01 0.58 1.00 1.00 0.99 0.70 1.00 0.99 
Current cigarette smoker 1.16 0.48 1.06 0.70 1.37 0.26 0.97 0.80 
Hypertension requiring tx 1.45 0.070 1.25 0.11 2.59 0.011 0.83 0.061 
History of MI 0.97 0.83 1.18 0.096 0.99 0.96 0.98 0.78 
History of CHF req tx 2.73 <0.001 1.96 <0.001 3.16 <0.001 1.04 0.82 
Cerebrovascular accident, TIA 1.20 0.31 1.59 <0.001 1.05 0.86 1.24 0.083 
Non-coronary artery disease 1.43 0.0079 1.18 0.10 1.54 0.027 1.09 0.38 
Neuropathy: clinical MNSI > 2 1.36 0.020 1.23 0.033 1.37 0.10 1.09 0.27 
Canada 0.50 0.0068 0.70 0.027 0.55 0.095 1.05 0.66 
Mexico 2.07 0.036 1.97 0.0038 2.25 0.077 0.60 0.060 
Brazil 1.63 0.010 0.99 0.97 1.32 0.32 0.32 <0.001 
Europe 1.96 0.023 1.31 0.27 1.44 0.44 0.82 0.43 
*Cox models for death, death/MI/Stroke, and cardiac death were stratified by randomized cardiac treatment strategies.   
*Effect modification between prompt revascularization and CABG stratum in model for subsequent procedure: <0.001.  
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Figure 2 continues. +: age <55; -x- age: 55-60; Δ age: 60-65; □ age: 65-70; ○ age:>=70; 
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Figure 2: Health status measures by time and 5-year age categories. +: age <55; -x- age: 55-60; Δ age: 60-65;  □ age:   
65-70; ○ age:>=70; 
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Table 4: Change in health status score by 5 year age groups. 
 
<55 [55,60) [60,65) [65,70) >=70 
 
Est. P Est. P Est. P Est. P Est. P 
DASI 
Year 1 versus Baseline 3.61 *   2.82 * 1.99 * 2.17 * 1.13 0.051 
Year 2 versus Baseline 3.08 * 2.48 * 1.17 0.049 2.04 0.002 0.41 0.50 
Year 3 versus Baseline 3.06 * 1.15 0.087 1.35 0.032 0.85 0.22 -1.41 0.029 
Year 4 versus Baseline 2.30 * 1.14 0.10 0.88 0.18 -0.13 0.86 -1.85 0.0066
Energy 
Year 1 versus Baseline 5.86 * 7.29 * 5.50 * 4.16 * 3.77 * 
Year 2 versus Baseline 6.21 * 7.97 * 6.28 * 4.49 * 2.08 0.035 
Year 3 versus Baseline 7.59 * 7.21 * 6.51 * 2.93 0.0061 1.45 0.14 
Year 4 versus Baseline 8.10 * 7.52 * 6.22 * 1.61 0.16 -0.78 0.46 
Health Distress 
Year 1 versus Baseline -10.88 * -10.83 * -8.07 * -7.11 * -6.56 * 
Year 2 versus Baseline -11.88 * -11.51 * -8.18 * -8.32 * -5.56 * 
Year 3 versus Baseline -13.90 * -10.45 * -9.16 * -7.99 * -4.62 * 
Year 4 versus Baseline -15.14 * -10.93 * -8.73 * -7.76 * -3.38 0.011 
Self-rated health 
Year 1 versus Baseline 7.64 * 11.52 * 8.01 * 9.26 * 4.41 * 
Year 2 versus Baseline 7.80 * 11.42 * 8.06 * 8.80 * 3.67 0.001 
Year 3 versus Baseline 8.70 * 11.56 * 8.68 * 8.64 * 4.00 * 
Year 4 versus Baseline 8.03 * 10.26 * 7.08 * 9.27 * 2.59 0.033 
 
1. * stands for p<0.001. 
2. Estimates are based on models for health status controlled for 5-year baseline age groups, categorical  
follow-up time, and interaction between 5-year baseline age groups and follow up time, random site effect,  
and missing data pattern. 
3. P values for interaction between 5-year baseline age groups and follow-up time on health status:  
    0.0021 for DAIS, <0.001 for Energy and Health Distress, and 0.0022 for self-rated health.   
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Figure 3: Effect of randomized ischemic treatment on health status, in all 2,163 patients and by 5-year baseline age 
groups. Interaction p values were for the interaction between centered baseline age and randomized treatment.Overall 
estimates were based on models controlled for strata, centered baseline age, continuous follow-up time, and 
interaction between centered baseline age and follow-up time(except for self-rated health), baseline health status, 
angina, random site effect, missing data pattern.  
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Figure 4: Effect of randomized glycemic treatment on health status, in all 2,163 patients and by 5-year baseline age 
groups. Interaction p values were for the interaction between centered baseline age and randomized treatment. 
Overall estimates were based on models controlled for centered baseline age, continuous follow-up time, and 
interaction between centered baseline age and follow-up time (except for self-rated health), baseline health status, 
random site effect, missing data pattern.  
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Table 5: Multivariable regression models for health status outcomes during BARI 2D follow-up. 
DASI (0-58.2) Energy (0-100) Health  Distress (0-100)
Self-Rated  
Health (0-100) Baseline variables 
  
Est p  Est p  Est p  Est p  
1 year increase in baseline age -0.16 <0.001 0.013 0.75 -0.18 <0.001 -0.048 0.23 
Follow-up -0.66 <0.001 -0.26 0.061 -0.16 0.34 -0.21 0.19 
Interaction (baseline centered age and follow 
up) -0.033 0.0015 -0.089 <0.001 0.091 <0.001   
REV versus MED 1.24 0.0012 1.16 0.043 -0.36 0.59 1.72 0.0066
IS versus IP 0.51 0.18 -0.31 0.58 -0.52 0.42 1.01 0.11 
CABG stratum 0.61 0.18 1.60 0.018 -2.24 0.0038 3.08 <0.001
Baseline health status measure 0.51 <0.001 0.43 <0.001 0.41 <0.001 0.40 <0.001
Baseline angina status (reference: no angina)  0.66  <0.001  0.11  0.0062
   Stable CCS1/CCS2  -0.40 0.36 -2.52 <0.001 1.55 0.037 -2.30 0.0014
   CCS3/4 or unstable  -0.30 0.62 -1.40 0.12 1.22 0.23 -1.32 0.18 
Insulin use at entry -2.27 <0.001 -2.95 <0.001 2.84 <0.001 -3.10 <0.001
Male sex 2.58 <0.001 2.63 <0.001 -2.44 0.0017 2.10 0.0051
Body mass index -0.17 <0.001 -0.17 0.0022 0.17 0.0052 -0.25 <0.001
Current smoking -2.65 <0.001 -4.87 <0.001 4.84 <0.001 -6.42 <0.001
History of hypertension required treatment -1.40 0.007 -1.84 0.018 1.94 0.029 -1.01 0.24 
History of myocardial infarction 0.085 0.84 -1.38 0.031 0.91 0.22 -1.28 0.071 
History of congestive heart failure -1.71 0.041 -2.40 0.055 3.82 0.0078 -3.30 0.017 
History of stroke -0.87 0.20 -2.27 0.025 0.10 0.93 1.54 0.17 
History of non coronary artery disease -2.50 <0.001 -3.26 <0.001 3.35 <0.001 -3.40 <0.001
Clinical evidence of neuropathy -1.31 0.0015 -1.37 0.027 1.31 0.065 -1.54 0.024 
Missing status (reference: completers )  <0.001  0.0069  <0.001  <0.001
   Noncompliance -2.12 0.048 -2.25 0.16 3.19 0.084 -3.67 0.048 
   Dropout -2.32 <0.001 -2.76 0.0032 3.84 <0.001 -4.19 <0.001
Intercept 18.2 <0.001 42.89 <0.001 7.57 0.002 40.87 <0.001
 *Model controlled for random site effect.  
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Year1 Year2 Year3 Year4
10 yr younger (52.4) 1.6 1.27 0.94 0.61
Mean age (62.4) 0 -0.66 -1.32 -1.98
10 yr older (72.4) -1.6 -2.59 -3.58 -4.57
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Figure 5: Interpretation of multivariate model results for health status outcomes, using DASI as an example. 
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7.8 SUPPLEMENT MATERIALS  
7.8.1 Missing health status outcomes  
Compared to participants with at least one follow-up health status measure, the 205 participants who did not have 
any follow-up health status measure were older, and had higher proportion of being randomized to receive prompt 
revascularization, higher proportion of heart failure, and more sever angina. Their perceived Energy and self-rated health 
were lower at baseline. (Table S1) Among the 205 participants, the baseline clinical profile and health status for those 
who died at first year were similar to those who survived up to at least one year. (Table S1) Although patients not included 
in the analysis appeared to have more severe cardiovascular conditions and lower perceived health at baseline, 
missingness might not be due to procedure-related death (indicating by death at first year).  
All 2,163 participants in the analysis were alive at first year visit. The proportion of inactivation was much lower in 
participants in the analysis than those who were not included. (Table S2)For the 205 participants not included in the 
analysis, the proportions of death and inactivation increased with follow-up years. (Table S3) 
Three strategies were used in the analysis to manage missing data, the first was using linear mixed model, and 
incorporated in the model covariates that were likely to contribute to missingness (for example, baseline angina status). 
The assumption for missingness in the model was missing at random. The second was to incorporate a categorical 
variable for missing pattern (completer, non-compliance and dropouts) in the linear mixed model to account for possible 
missing not at random. As the result, estimates of main covariates of interest, for example, age, would be averaged over 
missing patterns. The third strategy was to impute all missing health status outcomes for the 2,368 participants. The 
imputation was generated by multiple imputation method with based on important baseline covariates, baseline health 
status measures, and follow-up health status measures incorporated in the imputation function. Sensitivity analysis was 
then performed. The estimates generated from multiple imputed dataset were compared to the original data. Consistent 
results were showed in the sensitivity analysis.  (Table S4 and S5)  
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Table S1: Missing health status outcomes: baseline characteristics and health related quality of life by patients with or 
without one follow up quality of life data. 
 2,368 BARI 2D participants 205 patients not in the analysis
 Patients with at least one follow up data 
Patients without any follow 
up data p 
Died 
during yr1
Not died 
during yr1 p 
 n=2163 n=205  n=69 n=136  
Prompt revascularization (%) 49.0 57.1 0.026 62.3 54.4 0.28 
Insulin sensitizing (%) 49.9 50.2 0.93 53.6 48.5 0.49 
CABG stratum (%) 32.4 30.2 0.53 39.1 25.7 0.049 
Age (Mean) 62.3 63.7 0.039 64.3 63.5 0.59 
Male (%) 70.6 67.3 0.32 69.6 66.2 0.63 
Current Smoking (%) 12.2 16.0 0.12 9.0 19.5 0.054 
BMI (Mean) 31.8 31.4 0.45 31.1 31.5 0.72 
Prior MI(%) 31.6 36.7 0.14 42.6 33.6 0.21 
Heart Failure (%) 6.2 11.6 0.0036 14.7 9.9 0.32 
Angina (%)   0.0021   0.39 
None/Angina Equivalent 39.7 35.6  40.6 33.1  
Stable CCS I or II 43.0 37.1  37.7 36.8  
Stable CCS III or IV 17.3 27.2  21.7 30.1  
Duration of Diabetes (Mean) 10.3 11.6 0.089 13.0 10.8 0.15 
Insulin Use (%) 27.6 31.3 0.25 35.3 29.3 0.39 
DASI (Mean) 19.1 17.3 0.081 15.6 18.2 0.22 
Energy (Mean) 51.9 44.9 <0.001 46.4 44.0 0.49 
Health Distress (Mean) 40.3 42.4 0.29 38.4 44.8 0.12 
Self-Rated Health (Mean) 38.9 35.5 0.050 33.3 36.8 0.32 
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Table S2: Missing quality of life data due to death or inactivation (n=2163 patients who had at least 1 follow-up health 
status measure—who lived at least to year 1) 
 Year 1 (33 missing) Year 2 (140 missing) Year 3 (229 missing) Year 4 (312 missing)
 Frequency Percent Frequency Percent Frequency Percent Frequency Percent
Missing not due to death or inactivation 33 100 91 65 110 48.0 136 43.6 
Death 0 0 36 25.7 83 36.2 129 41.4 
Inactivation 0 0 13 9.3 36 15.7  47 15.1 
 
* At year 4, in the 185 patients died or in the inactivation status (they may be inactivated during year 4 or had been inactivated during previous 
time), 5 patients (4 deaths and 1 inactivation) had quality of life information, and 4 patients died after close out, their loss of data thus not 
considered as missing. Therefore, only 176 death or inactivation were with missing year 4 quality of life data.  
 
 
Table S3: Death and inactivation in year 1 for the 205 patients who did not have at least 1 follow-up health status measure. 
 Year 1  Year 2  Year 3  Year 4  
 Frequency Percent Frequency Percent Frequency Percent Frequency Percent
Missing not due to death or inactivation 56 27.3 27 13.2 27 13.2 23 11.2 
Death  69 33.7 83 40.5 85 41.5 88 42.9 
Inactivation 80 39.0 95 46.3 93 45.4 94 45.9 
*During the whole BARI 2D study period, 99 deaths (including 19 deaths after inactivation), 107 inactivation (100 inactivation without reactivation) 
and 7 reactivations occurred in these 205 patients.  
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Table S4: Sensitivity analysis—compare estimates in original data (N=2,163) versus 
multiple imputed data (N=2,368). 
 
Original Imputed  
Est P Est p 
DASI 
   REV vs. MED 1.32 <0.001 1.12 0.0035 
   Centered age -0.14 <0.001 -0.13 <0.001 
   Time -0.66 <0.001 -0.5 <0.001 
   Centered age and time -0.033 0.0013 -0.014 0.16 
Energy  
   REV vs. MED 1.35 0.022 1.37 0.03 
   Centered age 0.026 0.5187 0.009 0.84 
   Time -0.26 0.062 -0.23 0.12 
   Centered age and time -0.089 <0.001 -0.064 <0.001 
Health Distress 
   REV vs. MED -0.47 0.49 -0.21 0.76 
   Centered age -0.19 <0.001 -0.14 0.0025 
   Time -0.16 0.34 -0.069 0.65 
   Centered age and time 0.092 <0.001 0.085 0.0013 
Self rated health 
   REV vs. MED 1.76 0.0068 1.44 0.02 
   Centered age -0.0017 0.96 -0.0051 0.9 
   Time -0.21 0.19 -0.11 0.63 
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Table S5: Imputed data: multivariable regression models for health status outcomes during BARI 2D follow-up. 
DASI (0-58.2) Energy (0-100) Health Distress (0-100)
Self-Rated 
Health (0-100) 
Baseline variables 
 
 Est p  Est p  Est p  Est p  
1 year increase in baseline age -0.16 <0.001 -0.0074 0.87 -0.14 0.0083 -0.051 0.24 
Follow-up -0.50 <0.001 -0.23 0.12 -0.065 0.67 -0.11 0.65 
Interaction (baseline centered age and follow up) -0.01 0.15 -0.064 <0.001 0.085 0.0018   
REV versus MED 1.05 0.0049 1.20 0.062 -0.12 0.85 1.40 0.021 
IS versus IP -0.51 0.17 0.36 0.52 0.63 0.35 -1.06 0.080 
CABG stratum 0.44 0.31 1.47 0.024 -2.09 0.0047 2.79 <0.001
Baseline health status measure 0.5 <0.001 0.44 <0.001 0.39 <0.001 0.39 <0.001
   Stable CCS1/CCS2  -0.46 0.27 -2.23 <0.001 1.30 0.11 -1.98 0.0041
   CCS3/4 or unstable  -0.30 0.59 -1.23 0.17 1.45 0.15 -1.07 0.34 
Insulin use at entry -2.00 <0.001 -2.65 <0.001 2.66 <0.001 -2.89 <0.001
Male sex 2.45 <0.001 2.48 <0.001 -2.23 0.0045 1.82 0.015 
Body mass index -0.17 <0.001 -0.15 0.0071 0.15 0.021 -0.24 <0.001
Current smoking -2.37 <0.001 -4.45 <0.001 4.41 <0.001 -5.99 <0.001
History of hypertension required treatment -1.28 0.012 -1.62 0.043 1.86 0.028 -0.73 0.38 
History of myocardial infarction 0.16 0.70 -1.13 0.10 0.70 0.35 -1.03 0.20 
History of congestive heart failure -1.03 0.18 -1.80 0.16 3.01 0.03 -2.32 0.22 
History of stroke -0.66 0.32 -2.06 0.035 0.43 0.72 0.68 0.59 
History of non coronary artery disease -2.18 <0.001 -2.96 <0.001 3.01 <0.001 -2.94 0.0032
Clinical evidence of neuropathy -1.32 <0.001 -1.21 0.044 1.49 0.034 -1.39 0.049 
 *Model controlled for random site effect.  
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8. Paper three: longitudinal relationship between BMI and health status in the 
Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. 
 
8.1 ABSTRACT 
BACKGROUND:   This study investigated the longitudinal association between health 
status and body mass index (BMI) during 4 years of follow-up. 
METHODS:   Longitudinal analysis was performed on the data of the Bypass 
Angioplasty Revascularization Investigation 2 Diabetes trial. Health status outcomes 
included the Duke Activity Status, Energy/fatigue and health distress scales, and self-
rated health. BMI and health status were measured concurrently at each annual follow-
up visit. Variation in BMI measures was separated into between-person and within-
person change when modeling the longitudinal association between repeated BMI and 
health status outcomes. 
RESUTLS:   At baseline and each follow-up year, higher BMI was associated with 
poorer health status outcomes. In multivariable analysis, higher mean follow-up BMI 
(between-person BMI) was significantly associated with lower health status outcomes. 
The within-person BMI change was inversely associated with DASI, Energy and self-
rated health outcomes. The relationships between DASI or Energy and within-person 
BMI change appeared to be curvilinear, and differed by baseline obesity status.  
DISCUSSION:   The present study reported an inverse association between BMI and 
health status outcomes in patients with both stable ischemic heart disease and type 2 
diabetes. Weight reduction was desirable for obese patients, but may not be necessary 
for overweight but non-obese patients in order to achieve improved functional capacity 
and perceived Energy outcomes. 
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8.2 BACKGROUND 
The prevalence of obesity has been largely increasing during the past decades,88 in 
2000, more than half of American adults were estimated to be overweight or obese89. 
Obesity is a known risk factor for type 2 diabetes and coronary artery disease.90 Cross-
sectional studies have showed that being overweight or obese contributes to lower in 
health-related quality of life.91 However, little is known about the longitudinal relationship 
between obesity and health status. In the baseline analysis of BARI 2D, obesity was 
inversely associated with health status outcomes in patients with diabetes and coronary 
artery disease, and the relationship was independent of baseline comorbidities and 
treatment.92  
Another important aspect in the assessment of longitudinal association between 
obesity and health status is the within-person variability in weight. Weight fluctuation 
has been showed to be associate with increasing mortality and cardiovascular 
morbidity. 93 , 94  It is unclear whether within-person weight variability associate with 
change in health status outcome, and if the relationship differ by obesity status.    
       In this study, we investigated the longitudinal relationship between obesity and 
health status outcomes, accounting for the between-person BMI difference, within-
person BMI change, and potential interaction with obesity at baseline.   
 
8.3 METHODS 
8.3.1 Study Setting 
       The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) was 
a 2-by-2 factorial randomized trial that compared treatment strategies for patients with 
both stable ischemic heart disease and type 2 diabetes. The baseline characteristics 
and primary findings of BARI 2D had been reported in the literature.43, 46 Briefly, patients 
were eligible for BARI 2D if they had type 2 diabetes, documented myocardial ischemia, 
and angiographically documented coronary heart disease suitable for revascularization. 
Consented patients were randomized to receive one of the two randomized heart 
disease treatments—prompt revascularization or medical therapy with a delayed 
revascularization when necessary, and simultaneously randomized to one of the two 
glycemic treatments— insulin sensitizing or insulin providing drug to achieve a serum 
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Hemoglobin A1c level of less than 7.0%.  At total of 2368 patients were enrolled 
between January 2001 and March 2005, and the trial ended on November 30, 2008.  
The average patient follow-up was 5.3 years. 
 
8.3.2 Variables 
       Body mass index (BMI) was measured for each BARI 2D participant at study entry 
and each clinical visit. BMI was calculated as weight (in kilograms) divided by height (in 
meters). Health status was assessed at baseline and at each annual follow-up visit by 
four instruments—the Duke Activity Status Index (DASI),20 RAND Medical Outcome 
Study Energy/fatigue and health distress scales, and self-rated health. The score 
ranges from 0-58.2 for DASI, 0-100 for the Energy/fatigue. Self-rated health was 
measured in a five-category Likert scale and can be scored as a 0-100 continuous 
score.46 A higher score indicates better health status. For health distress, a higher score 
means more distress, therefore lower scores are better.   
 
8.3.3 Statistical Analysis  
       Data was truncated at year 4, since a number of patients did not have a year 5 
clinical visit, since they entered late in the recruitment period. Only patients with at least 
one follow-up health status measure were included in the analysis. Baseline 
demographic, clinical, and health status profile were summarized by BMI categories of 
normal (BMI<25), overweight (25≤BMI<30), class I obesity (30≤BMI<35), and class II/III 
obesity (BMI≥35). Continuous variables were compared with Student's t-test and 
categorical variables with chi-square statistics. For exploratory analysis, the population 
means for health status and BMI were displayed at baseline and each follow-up year. 
The total variability in repeated health status and BMI measures were analyzed by 
separating the between-person and within-person variance components. 95 
Nonparametric graphic display (Lowess smoothing plots) was used to show the 
relationship between health status and BMI. To investigate the potential feedback 
relationship between health status outcomes and BMI, the association between lagged 
BMI and health status and between lagged health status and BMI were explored. 
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The longitudinal analysis was performed by multilevel modeling under the structure 
of a linear mixed model. BMI and health status were measured concurrently at each 
annual follow-up visit. Year one follow-up was parameterized as the first repeated 
measure, and baseline health status value was included as a covariate. In modeling the 
association between BMI and health status, the between-person and the within-person 
change in repeated measured BMI was calculated. The between-person difference is 
defined as the difference between the overall mean BMI and the individual patient mean 
BMI value, averaged over follow-up years for each participant. The within-person 
change was calculated by subtracting the individual mean value from the BMI measures 
at each different follow-up year.96,97,98The modeling strategy was selected not only for 
the examination in within-person weight change and health status, but also for its ability 
to relax the homogeneous variance assumption in the linear mixed effect model.99   
       The model incorporated two random slopes to allow health status to differ by 
individuals and health status to fluctuate as BMI changes within an individual. The basic 
multilevel model for the longitudinal association between BMI and health status was 
listed in the appendix.  
       The assumption of linear association between BMI and health status outcomes was 
first graphically examined by Lowess smoothing curves, and then tested by adding a 
quadratic BMI variable in the model and estimated its significance. To control for 
potential confounders in the association between BMI and health status outcomes, 
multivariate models were constructed. Potential confounders at baseline including 
CABG stratum, sex, smoking, age, angina severity, insulin use, history of hypertension, 
congestive heart failure, myocardial infarction, stroke, non-coronary artery disease, and 
clinical neuropathy. A categorical variable for geographic region was also included in 
the model. Effect modification between within-person BMI change and randomized 
treatment, intended revascularization methods, follow-up time, sex, race, and baseline 
obesity were tested in multivariate models. To control for multiple comparisons, the 
significance level of polynomials and effect modification were set to a two-sided alpha of 
0.01. 
Missing baseline covariates was managed by mean values imputation, calculated 
separately by the intended revascularization method. In health status analysis, missing 
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outcomes were identified if a patient did not provide health status data at annual follow-
up visit, with an exception of administrative censoring. Under the missing at random 
assumption in mixed model, missing outcomes were not imputed. To account for 
potential missing not at random, a categorical variable for three missing patterns: 
completers (no missing), noncompliance and dropouts was added as a covariate in the 
models.27 To investigate if waist circumference can serve as an obesity measure 
alternative for the study, the association between health status and waist circumference 
was explored, and mixed effect models were constructed using either waist 
circumference alone or a 9-category variable combing BMI and waist circumference 
percent change from baseline levels (-5%<, [-5%,5%], >5%). To account for the 
influence of languages and cultures on health status response of participants from 
different countries, a sensitivity analysis was performed on data from US or Canada 
participants only. Analyses are performed with SAS statistical software (version 9.1; 
SAS Institute Inc, Cary, NC). 
 
8.4 RESULTS 
        2,163 of the 2,368 (93.6%) BARI 2D participants with at least one follow-up health 
status measure were included in the analysis. At baseline, 1,219 (56.4%) participants 
were obese. Participants in higher baseline BMI categories were younger, and with 
higher proportions of female, African American and from sites in the United States. At 
baseline, obesity was associated with higher proportion of insulin use, history of 
congestive heart disease or chronic renal dysfunction, but inversely associated with 
smoking and history of myocardial infarction. The baseline distributions of serum HbA1c, 
duration of diabetes, and clinical history of neuropathy, angina, stroke or non-coronary 
artery disease were similar across BMI categories (Table 1). 
       Health status measures significantly improved from baseline to year one visit, and 
then gradually decline during follow-up years (Figure 1). The mean BMI at baseline and 
year one were similar, and increased gradually at later follow-up years (Figure 2). 
Results from lagged analysis showed one unit increase in preceding BMI was 
significantly associated with lower subsequent health status (-0.25 for DASI, -0.37 for 
Energy, 0.41 for health distress and -0.47 for self rated health, p all <0.001), while one 
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unit decrease in health status was associated with greater subsequent BMI (0.005 unit 
increase in BMI for one unit decrease in DASI (p<0.03), Energy (p <0.001), self-rated 
health (p <0.001). 0.003 unit increase in BMI for one unit increase in health distress, p 
<0.001).  
        The analysis of variance results showed notable within-person variability in health 
status outcomes (Table 2). Although the within-person variability in BMI was relatively 
small,  as follow-up year increases, more participants had larger BMI percent change 
from baseline (participants with more than 5 % BMI increase from baseline: 20.5% at 
year 1, 28.7% at year 2, 32.8% at year 3 and 34.4% at year 4) (Figure 3). The mean 
BMI during follow-up, as the averaged between-person BMI value, was 32.1 for all 
participants, 35.7 for participants who were obese at baseline and 27.3 for participants 
who were non-obese at baseline. The mean within-person BMI change, as the 
difference in follow-up BMI measure of a participant from his/her follow-up BMI mean, 
averaged over the 2,163 participants, was -0.27 at year one, 0.04 at year two, 0.11 at 
year three, and 0.16 at year four.   
        At baseline and each follow-up year, higher BMI was associated with poorer health 
status, especially for participants with class II/III obesity at baseline (Table 3).  
Exploratory smoothing plots showed a nonlinear association between health status and 
BMI. For example, the highest mean DASI score was observed at a BMI between 26 
and 30; for obese participants with BMI greater than 30 kg/m2, higher BMI was linearly 
associated with lower DASI. When the variability in repeated BMI measures is 
separated into between and within person change, the association between DASI and 
within-person BMI change appeared to be curvilinear, indicating a quadratic fit (Figure 
4). 
        In multivariable analysis, one unit increase in mean follow-up BMI, as one unit 
change in between-person BMI, was significantly associated with lower health status 
outcomes (0.28 point lower in DASI, 0.34 point lower in Energy, 0.24 point more 
distress and 0.36 point lower in self-rated health, p all <0.001). The within-person BMI 
change, as the difference in a person’s follow-up BMI measures from his or her mean 
follow-up BMI, was inversely associated with DASI, Energy and self-rated health 
outcomes.  
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The relationships between DASI or Energy and within-person BMI change 
appeared to be curvilinear, and differed by baseline obesity status. For participants who 
were obese at baseline, increase within-person BMI by one unit was associated with 
worse health status (0.39 point decrease in DASI, and 0.65 point decrease in Energy), 
while decrease within-person BMI by one unit was associated with better health status 
(0.27 point increase in DASI and 0.43 point increase in Energy). For participants who 
were non-obese at baseline, either increase or decrease in within-person BMI was 
associated with lower DASI and Energy (one unit increase: -0.29 point decrease in 
DASI and Energy; one unit decrease: -0.61 and -1.11 point decrease in DASI and 
Energy) (Table 5). The association between follow-up BMI and DASI is illustrated in 
figure 5.  
For self-rated health, a one unit increase in within-person BMI change was 
associated with 0.39 point decrease in averaged score (p=0.02). Within-person change 
in BMI was not significantly associated with perceptions of health distress in participants.  
BMI and waist circumference was highly correlated in the current study data. 
Results showed that the averaged percent change in BMI had larger effect than waist 
circumference on health status outcomes. In sensitivity analysis restricted to only 
participants from the United States and Canada, similar associations between BMI and 
health status were observed. Although the significance for curvilinear relationship and 
effect modification decreased in the sensitivity analysis, the magnitudes of coefficients 
were similar in the two populations. 
 
8.5 DISCUSSION 
Longitudinally, higher BMI was associated with lower health status outcomes in 
patients with both stable coronary heart disease and type 2 diabetes, the association 
was independent of the effects of demographics and obesity-associated morbidity.   
Differences in BMI between patients as well as changes in BMI over time within an 
individual patient were important determinants for health status. In the study, repeated 
BMI measures for each participant was separated into mean BMI during follow-up, 
which was constant over time for an individual, and the within-person BMI change, 
which represents the fluctuation in BMI over time compared to the individual patient’s 
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mean value. To illustrate the main finding of the study, a non-obese patient with mean 
follow-up BMI of 27 had 2.8 point higher DASI, 2.4 point higher Energy, 2.4 point less 
health distress and 3.6 point higher self-rated health compared to an obese patient with 
mean follow-up BMI of 37. These differences are clinically important since a 3 point 
difference for DASI, and a 5 point difference for other health status measures are 
considered clinically meaningful.   
BMI is a modifiable risk factor of morbidity, and lifestyle intervention programs often 
use percent weight change as a primary goal for overweight and obese patients. In 
current study, One unit reduction from individual mean follow-up BMI was significantly 
associated with a small increase in self-rated health for all participants, and a small 
increase in DASI and Energy for patients who were obese at baseline. However, both 
positive and negative within-person BMI changes were associated with decrease in 
DASI and Energy for patients who were not obese at baseline.   
Obesity was prevalent in our study participants who had heart disease and 
diabetes. Although BARI 2D patients were counseled about weight loss and exercise, 
the observed trend of increasing mean BMI over time in the study was not unexpected, 
since diabetes treatment is known to be associated with weight gain. Moreover, at study 
entry, the mean age of participants was 62.3 years, and increase in BMI was expected 
as a result of the natural shift of body composition.100 The present study suggests that 
weight reduction is desirable for obese patients. Obesity is a known risk factor for both 
heart disease and type 2 diabetes. The increasing adipokines secreted by excessive 
adipose tissue may lead to systemic inflammation and insulin resistance. 101 , 102 
Inflammatory factors have been showed associated with risk of sarcopenia, bone loss, 
and anemia,103,104,105leading to decline in functional capacity and health status.  
It is notable that our results suggest that weight reduction may not be desirable for 
patients who were overweight but non-obese, since weight gain and weight loss were 
each associated with worsening DASI and Energy outcomes. One possible explanation 
is the normal increase in BMI with age. In previous literature, the Epidemiologic Studies 
of the Elderly reported that disability-free life expectancy was greatest among the 
overweight individuals with a BMI of 25-30.106 Previous research also indicated that the 
body required necessary amount of fat storage to buffer the low caloric intake during 
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acute illness and wasting in chronic conditions.107 The current study suggests that a 
stable BMI for non-obese patients was associated with better functional capacity and 
perceived energy outcomes. 
Due to the shift in body composition and adiposity, waist circumference has been 
suggested as an effective measure of adnominal obesity. 108  In selecting the most 
appropriate method to define obesity, the associations between BMI, waist 
circumferences and health status were investigated. Current study reported change in 
BMI had larger effect on health status outcomes than waist circumference. Considering 
waist circumference was more susceptible to measurement error, we select BMI as the 
main covariate of interest in the present study.  
It is also possible that health status may influence BMI measures. The study 
reported the association between lagged BMI and health status was greater and more 
significant than the association between lagged health status and BMI. Similar 
observations were reported in the literature, as the changes of BMI on health 
trajectories were more influential than the changes of health on BMI trajectory.97 Thus, 
the present study used single direction model for the longitudinal association between 
BMI and health status outcomes.  
A complication in the study would occur if participants available in the latter period 
of the study were likely to report better health status results. However, the association 
between health status and BMI were similar at each follow-up time, indicating a minor 
survivor effect.  In addition, in multivariate analysis, the model controlled for missing 
patterns to adjust for possible missing not at random within the structure of mixed model, 
the estimates of BMI from the model thus were averaged over different missing 
scenarios.  
Compared to previous research, the strength of the present study is to investigate 
the longitudinal relationship between BMI and health status outcomes, in which the 
subtlety of weight change dynamics overtime was captured in the analysis. The study is 
also informative clinically in terms of improving health status with BMI management for 
patients with both heart disease and type 2 diabetes.  
 
 74 
8.6 CONCLUSION 
From the results of longitudinal analysis, the present study reports an inverse 
association between BMI and health status outcomes in patients with both stable 
coronary heart disease and type 2 diabetes. The association is independent of the 
effects of demographics and obesity-associated diseases.  Weight reduction over time 
is advantageous for obese patients, but may not be desirable for non-obese patients to 
improve functional capacity and perceived Energy outcomes.  
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8.7 TABLES AND FIGURES 
 
Table 1 Baseline characteristics by BMI categories for the 2,163 BARI 2D participants included in the analysis. 
Characteristic Under/normal(N=192) 
Overweight
(N=743) 
Class 1 obesity
(N=694) 
Class 2/3 obesity
(N=525) p-value
Age at study entry, mean, SD 61.7, 8.3 63.3, 8.8 62.9, 8.6 60.1, 8.9 <0.001 
Male, % 71.4 75.4 72.2 61.9 <0.001 
Region of World, % <0.001 
  USA 44.8 50.2 65.7 78.1  
  Canada 14.6 18.6 15.9 12.0  
  Mexico 12.0 6.1 1.2 0.8  
  Brazil 26.0 21.7 14.0 6.9  
  Czech Republic/Austria 2.6 3.5 3.3 2.3  
Race/Ethnicity, % <0.001 
  White non Hispanic 52.1 65.3 69.5 68.4  
  Black non Hispanic 13.5 14.0 17.3 20.0  
  Hispanic 23.4 13.2 11.0 9.5  
  Other non Hispanic 10.9 7.5 2.3 2.1  
Current cigarette smoking 17.7 12.7 11.2 10.9 0.071 
Number of years smoked, mean, SD 29.0, 13.9 28.1, 14.1 27.4, 13.6 25.4, 14.3 0.017 
Insulin use at baseline, % 18.2 22.7 28.5 36.6 <0.001 
Duration of DM, mean, SD 10.8, 8.4 10.3, 8.5 10.3, 8.6 10.2, 8.7 0.89 
HbA1c %: Core augmented with site estimate, mean, SD 7.8, 1.7 7.6, 1.6 7.6, 1.6 7.7, 1.6 0.29 
History of MI, % 37.7 34.4 29.9 27.4 0.012 
History of CHF, % 5.2 4.3 5.8 9.6 0.0015 
Baseline angina categories 0.16 
  None/Angina equivalent only 38.7 38.0 43.2 37.9  
  Stable CCS1/CCS2 45.5 45.1 41.1 41.7  
  Stable CCS3/CCS4/Unstable 15.7 17.0 15.7 20.4  
Clinical MNSI ≥ 2, % 47.9 48.5 51.7 51.6 0.51 
Non-coronary artery disease, % 26.0 22.6 23.5 23.6 0.80 
Cerebrovascular accident TIA, % 9.9 9.6 9.7 9.2 0.99 
Chronic renal dysfunction, % 0.5 2.0 3.2 4.6 0.009 
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Figure 1: Mean health status by time (2,163 BARI 2D participants included in the analysis). 
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Figure 2: Mean BMI by time (2,163 BARI 2D participants included in the analysis). Bars indicating 95% confidence level of 
standard error of the mean. 
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Table 2: Between and within subject variability (Data parameterization, year 1 as the first measurement.) 
 
Variables Source of variability Variance estimate 
Between-participant (σs2) 149.19 DASI 
Within-participant (σ2)  59.53 
Between-participant (σs2) 378.90 Energy 
Within-participant (σ2)  147.95   
Between-participant (σs2) 376.35 Health Distress 
Within-participant (σ2)  217.68 
Between-participant (σs2) 315.84 Self-rated Health 
Within-participant (σ2)  201.61 
Between-participant (σs2) 36.6 BMI 
Within-participant (σ2)  1.98 
* σs2: variance due to the difference in individual mean value (averaged over repeated measures) from population mean value.  
   σ2  : residual variance due to difference in individual repeated measures from individual mean.   
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Figure 3: Distribution of percent change in BMI from baseline by follow-up time.  Year 1: N=2114, year 2: N=2005, year 3: 
N=1918, year 4: N=1672. 
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Table 3: Mean health status by baseline BMI categories and time.  
Health status  Under/normal (N=192) 
Overweight
(N=743) 
Class 1 obesity
(N=694) 
Class 2/3 obesity 
(N=525) P
1 
DASI (0-58.2) 
Baseline 20.35 20.82 19.27 16.01 <0.001
Year 1 23.29 23.50 21.52 17.87 <0.001
Year 2 23.76 23.32 20.84 17.55 <0.001
Year 3 23.20 22.46 20.67 16.71 <0.001
Year 4 22.93 22.99 20.13 15.50 <0.001
Energy (0-100) 
Baseline 57.92 56.60 50.92 44.40 <0.001
Year 1 60.66 61.79 56.76 50.61 <0.001
Year 2 62.13 62.44 56.71 50.76 <0.001
Year 3 62.71 62.33 57.96 48.72 <0.001
Year 4 61.93 62.22 56.20 49.23 <0.001
Health distress (0-100) 
Baseline 38.74 36.92 39.70 46.47 <0.001
Year 1 28.98 27.53 31.63 37.93 <0.001
Year 2 27.89 27.17 30.35 37.58 <0.001
Year 3 27.28 27.32 28.90 38.34 <0.001
Year 4 26.23 26.61 30.42 37.46 <0.001
Self-rated health (0-100) 
Baseline 36.85 42.12 39.67 34.12 <0.001
Year 1 45.92 50.34 47.30 42.26 <0.001
Year 2 47.13 50.81 47.32 41.60 <0.001
Year 3 51.76 50.77 48.03 40.52 <0.001
Year 4 50.16 50.95 47.16 39.49 <0.001
1 p value of one-way ANOVA test at each time. 
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Figure 4: Lowess smoothing plots for DASI by BMI at year 1 and 4; DASI by between-person and within-person BMI 
change at year 1.
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 Table 5: summary results of multivariate model (N=2,163). 
DASI Energy Health distress Self-rated health Effect 
Estimate p Estimate p Estimate p Estimate p 
One unit increase in mean follow-up BMI  
(Between-person BMI difference, βBSBMI) -0.28 <0.001 -0.34 <0.001 0.24 <0.001 -0.36 <0.001
Within a person, one unit difference in each follow-up BMI measure  
from mean follow-up BMI (Within-person BMI difference, βWSBMI) -0.023 0.89 -0.39 0.020 
βWSBMI for baseline obese patients  -0.33 <0.001 -0.54 <0.001
Quadratic βWSBMI for baseline obese patients  -0.062 0.023 -0.11 0.01 
βWSBMI for baseline non-obese patients  0.16 0.37 0.41 0.13 
Quadratic βWSBMI for baseline non-obese patients  -0.45 <0.001 -0.7 <0.001   
IS versus IP 0.49 0.21 -0.39 0.5 -0.49 0.47 0.80 0.21 
REV versus MED 1.3 <0.001 1.34 0.022 -0.52 0.43 1.79 0.0055
CABG stratum 0.45 0.31 1.6 0.018 -1.94 0.011 3.13 <0.001
Follow-up year (continuous) -0.61 <0.001 -0.19 0.17 -0.22 0.20 -0.10 0.53 
Baseline health status measure 0.52 <0.001 0.43 <0.001 0.40 <0.001 0.39 <0.001
Baseline obesity (BMI ≥ 30) 0.45 0.42 0.95 0.25   
Age at baseline -0.23 <0.001 -0.11 0.0032 -0.065 0.14 -0.076 0.066 
Male 1.94 <0.001 1.7 0.013 -1.81 0.02 1.49 0.048 
Race/ethnicity (ref: white)  <0.001  <0.001  <0.001  <0.001
   Black 0.39 0.5 3.77 <0.001 -1.68 0.087 0.44 0.64 
   Hispanic -2.85 <0.001 -0.3 0.78 6.51 <0.001 -4.38 <0.001
   Other -2.46 0.0087 -1.55 0.27 1.61 0.31 -3.67 0.018 
Angina categories (ref: None/angina equivalent only)  0.095  <0.001  0.0058  <0.001
   Stable CCS1/CCS2 -0.91 0.038 -3.31 <0.001 2.35 0.0017 -2.90 <0.001
   Stable CCS3/CCS4/Unstable -0.86 0.14 -2.45 0.0058 1.9 0.058 -1.87 0.056 
Baseline insulin use -2.25 <0.001 -2.97 <0.001 2.87 <0.001 -3.23 <0.001
Current Smoking  -3.29 <0.001 -5.94 <0.001 5.69 <0.001 -7.20 <0.001
History of hypertension required treatment -1.35 0.0099 -2.06 0.0089 2.01 0.025 -0.93 0.29 
History of myocardial infarction -0.13 0.77 -1.57 0.016 1.18 0.11 -1.49 0.038 
History of congestive heart failure -1.16 0.17 -1.29 0.31 2.88 0.046 -2.95 0.035 
History of stroke -0.95 0.16 -2.25 0.029 0.15 0.90 1.28 0.26 
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Table 5 continue. 
History of non coronary artery disease -2.3 <0.001 -2.72 <0.001 2.94 <0.001 -2.99 <0.001
History of chronic renal dysfunction -1.44 0.23 -2.35 0.19 2.90 0.16 -2.03 0.31 
Clinical evidence of neuropathy -1.18 0.0034 -1.26 0.038 1.27 0.067 -1.38 0.039 
Country  <0.001  <0.001  <0.001  <0.001
Brazil 0.99 0.13 16.8 <0.001 -12.47 <0.001 10.86 <0.001
Canada 1.5 0.011 3.06 <0.001 -0.31 0.76 2.13 0.031 
Czech Republic/Austria 5.84 <0.001 0.28 0.87 3.26 0.10 3.32 0.086 
Mexico 9.44 <0.001 6.02 0.0013 -14.95 <0.001 -3.41 0.096 
Missing status (reference: completers )  <0.001  0.0029  <0.001  <0.001
   Noncompliance -1.89 0.081 -2.63 0.1 2.76 0.14 -4.29 0.022 
   Dropout -2.38 <0.001 -2.96 0.0017 3.97 <0.001 -3.98 <0.001
Intercept 36.21 <0.001 54.16 <0.001 8.78 0.035 50.04 <0.001
 
*P value for quadratic within-person BMI change: :0.0013 for DASI and <0.001 for Energy. P value for interaction between baseline obesity and 
within-person BMI change: 0.0019 for DASI and <0.001 for Energy 
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Figure 5: Interpretation of averaged association of follow-up BMI and DASI. Assume mean follow-up BMI is 35 for 
participant who were obese at baseline, and 25 for participants who were non-obese at baseline.  Estimation formula:  
 [Obese at baseline] mean DASI=-0.28*(mean BMI during follow-up-25)-0.33*(within-person BMI change)-0.062*(within-
person BMI change)2  [Non-obese at baseline] mean DASI=-0.28*(mean BMI during follow-up-25)+0.16*(within-person 
BMI change)-0.45*(within-person BMI change)2* 
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8.8 FORMULA 
 
Using DASI as an example, the basic multilevel model for the longitudinal association between BMI and health status 
outcome can be described as below. 
 
At the individual level (within individual):  
DASIij= b0i+b1iBMIij+b2iyearj+b3ibaseline DASIi+eij 
BMIij= BMIij+ BMIi-BMIi = BMIi + (BMIij -BMIi) 
         DASIij= (b0i+ bBSBMIi)+bWS(BMIij -BMIi)+b2iyearj+b3ibaseline DASIi+eij 
 
DASIij: DASI for participant i at year j:  
b0i= year 1 DASI for participant i with both 0 in baseline and follow-up BMI. 
b1i= DASI difference for unit change in follow-up BMI for participant i. 
b2i= yearly DASI difference for participant i. 
b3i= DASI difference due to one unit increase in baseline value. 
 
bBS= DASI difference for unit change in mean follow-up BMI for participant i. 
bWS= DASI difference for unit change in follow-up BMI variability for participant i. 
 
At population level (between individual):  
b0’= β0+βBSBMI+v0i 
b1’= βWSBMI+v1i  
b2= β2+v2i 
b3= β3 
v0i = individual deviation from average intercept. 
v1i = individual deviation from average slope of yearly DASI change. 
v2i = individual deviation from average slope of DASI change associated with one unit difference in within person 
BMI variability. 
 
In the multilevel model, the averaged effect of follow-up BMI is βBSBMIi+ βWSBMI(BMIij -BMIi).  
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8.9 SUPPLEMENT FIGURES/TABLES 
 
Table S1: Pearson correlation coefficients and partial correlation coefficients for BMI, waist circumference and health 
status measures at baseline and each follow-up visit. 
 BMI Waist circumference DASI (0-58.2) Energy (0-100) 
Health Distress 
(0-100) 
Self-Rated 
Health (0-100) 
BMI       
Baseline 1 0.82 -0.16 -0.24 0.15 -0.11 
Yr1 1 0.81 -0.18 -0.27 0.23 -0.18 
Yr2 1 0.83 -0.20 -0.26 0.22 -0.18 
Yr3 1 0.84 -0.18 -0.29 0.23 -0.22 
Yr4 1 0.83 -0.20 -0.25 0.18 -0.22 
Waist circumference 
Baseline 0.82 1 -0.12 -0.24 0.12 -0.09 
Yr1 0.81 1 -0.17 -0.27 0.22 -0.16 
Yr2 0.83 1 -0.18 -0.26 0.21 -0.17 
Yr3 0.84 1 -0.18 -0.3 0.22 -0.23 
Yr4 0.83 1 -0.21 -0.26 0.19 -0.23 
BMI: Pearson Partial Correlation Coefficients 
Baseline 1  -0.12 -0.064 0.099 -0.064 
Yr1 1  -0.072 -0.083 0.099 -0.083 
Yr2 1  -0.096 -0.071 0.086 -0.073 
Yr3 1  -0.058 -0.076 0.072 -0.070 
Yr4 1  -0.056 -0.053 0.072 -0.079 
Waist circumference: Pearson Partial Correlation Coefficients 
Baseline  1 0.029 -0.089 -0.009 0.003 
Yr1  1 -0.046 -0.10 0.055 -0.032 
Yr2  1 -0.024 -0.098 0.050 -0.039 
Yr3  1 -0.050 -0.107 0.064 -0.066 
Yr4  1 -0.073 -0.109 0.048 -0.065 
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Table S2: Health status outcomes by BMI changes, controlled for confounders (N=1,673 participants from US or Canada). 
DASI Energy health distress Self-rated health Effect 
Estimate p Estimate p Estimate p Estimate p 
One unit increase in mean follow-up BMI  
(Between-person BMI difference, βBSBMI ) -0.26 <0.001 -0.34 <0.001 0.24 <0.001 -0.37 <0.001 
Within a person, one unit difference in each follow-up BMI measure  
from mean follow-up BMI (Within-person BMI difference, βWSBMI) 0.12 0.54 -0.41 0.018 
βWSBMI for baseline obese patients -0.29 0.0053 -0.60 <0.001 
Quadratic βWSBMI for baseline obese patients -0.053 0.060 -0.092 0.037 
βWSBMI for baseline non-obese patients 0.072 0.75 0.34 0.32 
Quadratic βWSBMI for baseline non-obese patients -0.33 0.012 -0.54 0.009   
IS versus IP 0.81 0.075 -0.47 0.48 -0.71 0.37 1.51 0.044 
REV versus MED 1.00 0.028 1.11 0.095 -0.49 0.54 1.62 0.031 
CABG stratum 0.46 0.40 2.28 0.0043 -2.62 0.0061 3.28 <0.001 
Follow-up year (continuous) -0.97 <0.001 -0.44 0.0052 0.042 0.83 -0.039 0.83 
Baseline health status measure 0.55 <0.001 0.47 <0.001 0.42 <0.001 0.42 <0.001 
Baseline obesity (BMI ≥ 30) 0.39 0.54 1.66 0.082   
Age at baseline -0.19 <0.001 -0.078 0.067 -0.096 0.063 -0.04 0.41 
Male 1.40 0.010 0.99 0.21 -0.61 0.52 1.58 0.077 
Race/ethnicity (ref: white)  <0.001  <0.001  <0.001  0.0022 
   Black 0.55 0.39 4.31 <0.001 -1.47 0.19 -0.49 0.64 
   Hispanic -2.51 0.001 0.080 0.94 6.35 <0.001 -4.2 <0.001 
   Other -2.66 0.0091 -1.12 0.45 1.39 0.43 -3.51 0.036 
Angina categories (ref: None/angina equivalent only)  0.080  <0.001   0.0081   0.0031 
   Stable CCS1/CCS2 -1.10 0.030 -4.10 <0.001 2.64 0.0027 -2.81 <0.001 
   Stable CCS3/CCS4/Unstable -0.97 0.15 -2.23 0.026 2.24 0.06 -1.98 0.079 
Baseline insulin use -2.19 <0.001 -2.59 <0.001 2.81 0.002 -2.84 0.001 
Current Smoking  -3.25 <0.001 -5.78 <0.001 5.68 <0.001 -7.4 <0.001 
History of hypertension required treatment -1.48 0.015 -2.05 0.022 1.81 0.087 -1.99 0.048 
History of myocardial infarction -0.43 0.40 -1.89 0.013 1.51 0.094 -1.43 0.093 
History of congestive heart failure -0.85 0.34 -1.04 0.42 2.76 0.076 -2.66 0.07 
History of stroke -1.12 0.14 -2.34 0.035 0.62 0.64 0.99 0.43 
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Table S2 continue. 
History of non coronary artery disease -2.07 <0.001 -2.83 <0.001 3.47 0.0003 -3.18 <0.001
History of chronic renal dysfunction -1.27 0.32 -2.38 0.21 2.06 0.36 -1.24 0.56 
Clinical evidence of neuropathy -1.26 0.0072 -1.63 0.018 1.54 0.061 -1.74 0.026 
Canada 1.72 0.0052 3.16 <0.001 -0.21 0.85 1.77 0.082 
Missing status (reference: completers )  <0.001  0.0044   <0.001   <0.001
   Noncompliance -2.25 0.058 -2.68 0.12 3.36 0.11 -3.96 0.054 
   Dropout -2.60 <0.001 -3.12 0.0024 4.77 <0.001 -3.92 <0.001
Intercept 33.43 <0.001 51.01 <0.001 8.83 0.072 47.37 <0.001
 
*P value for quadratic within-person BMI change: 0.021 for DASI and 0.013 for Energy. P value for interaction between baseline obesity and 
within-person BMI change: 0.10 for DASI and 0.009 for Energy. 
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8.9.1 Confounding due to adverse clinical event during follow-up 
      For all patients who experienced myocardial infarction, stroke or subsequent 
procedure during follow-up years, a greater proportion of participants lost weight 
after the event. (Table S3) Cardiovascular events appeared to be associated with 
reduction in BMI, especially at later follow-up years. (Table S4) Cardiovascular 
events also appeared to be associated with reduction in health status change 
from baseline, especially for functional capacity (DASI). (Table S4) Therefore, 
occurrence of myocardial infarction or stroke, and having subsequent procedure 
within a year prior to annual follow-up visit were confounders in the association 
between BMI and health status outcomes.     
      In the multivariate analysis with additional adjustment of cardiovascular event 
occurred within a year prior to annual visit, the quadratic association and effect 
modification between DASI or Energy and within-person BMI change remained 
similar and significant, indicating the association was independent of confounding 
factors. (Table S5) 
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Table S3: BMI change from Individual mean after clinical event occurred by 
baseline   obese status.  
Event (Person-events) BMI change fromIndividual mean  Non-obese Obese p 
N= 86 110 
Decrease,% 58.1 57.3 
No change,% 3.5 1.8 MI  
Increase,% 38.4 40.9 
0.74 
N= 23.0 23.0 
Decrease,% 65.2 60.9 
No change,% 4.4 4.3 Stroke 
Increase,% 30.4 34.8 
0.95 
N= 291 503 
Decrease,% 59.8 57.6 
No change,% 4.1 3.4 
Subsequent 
procedure 
Increase,% 36.1 39.0 
0.66 
N= 19 25 
Decrease,% 36.8 52.0 Cancer 
Increase,% 63.2 48.0 
0.32 
N= 50 113 
Decrease,% 36.0 44.2 
No change,% 2.0 1.8 
Chronic renal 
dysfunction 
Increase,% 62.0 54.0 
0.62 
 
Event (Persons) BMI change fromIndividual mean  Non-obese Obese p 
N= 79 94 
Decrease,% 59.5 59.6 
No change,% 2.5 2.1 MI  
Increase,% 38.0 38.3 
0.98 
N= 20 21 
Decrease,% 70.0 61.9 
No change,% 5.0 4.8 Stroke  
Increase,% 25.0 33.3 
0.84 
N= 224 363 
Decrease,% 60.3 57.8 
No change,% 3.6 3.6 
Subsequent 
procedure 
Increase,% 36.1 38.6 
0.84 
N= 19 25 
Decrease,% 36.8 52.0 Cancer 
Increase,% 63.2 48.0 
0.32 
N= 50 113 
Decrease,% 36.0 44.2 
No change,% 2.0 1.8 
Chronic renal 
dysfunction 
Increase,% 62.0 54.0 
0.62 
 
*Few patients had more than one event; therefore, the denominator in the upper table was 
person-events, and persons for the lower table.   
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Table S4: Health status change after clinical event occurred.  
MI/stroke  
occurred in prior year 
Subsequent procedure 
occurred in prior year Health status  
Follow
-up 
years No Yes P No Yes p 
Year 1 -0.28 -0.052 0.22 -0.25 -0.39 0.14 
Year 2 0.05 -0.26 0.14 0.058 -0.12 0.068 
Year 3 0.13 -0.57 0.006 0.13 -0.11 0.072 
BMI change from 
Individual mean   
Year 4 0.16 -0.14 0.31 0.17 -0.075 0.095 
Year 1 -0.29 0.13 0.16 -0.27 -0.33 0.67 
Year 2 0.025 -0.35 0.27 0.035 -0.16 0.19 
Year 3 0.13 -0.79 0.0034 0.14 -0.17 0.077 
BMI change from 
Individual mean for 
obese patients at 
baseline  Year 4 0.20 -0.14 0.45 0.20 0.018 0.40 
Year 1 -0.26 -0.30 0.79 -0.23 -0.50 0.0077
Year 2 0.082 -0.15 0.33 0.087 -0.067 0.10 
Year 3 0.12 -0.38 0.13 0.11 0.037 0.57 
BMI change from 
Individual mean  for 
non-obese patients 
at baseline Year 4 0.11 -0.14 0.46 0.13 -0.23 0.03 
Year 1 2.45 0.35 0.10 2.57 1.00 0.045 
Year 2 2.15 -6.45 <0.001 2.37 -2.73 <0.001
Year 3 1.39 -6.47 <0.001 1.6 -4.86 <0.001
DASI change from 
baseline 
Year 4 0.52 -2.16 0.36 0.65 -2.36 0.036 
Year 1 5.36 3.89 0.48 5.25 5.59 0.79 
Year 2 5.54 4.58 0.75 5.73 3.13 0.11 
Year 3 5.62 -1.53 0.096 5.80 0.28 0.0058
Energy change 
from baseline 
Year 4 4.79 3.41 0.82 4.94 1.80 0.23 
Year 1 -8.73 -8.62 0.97 -9.18 -5.80 0.035 
Year 2 -9.33 -4.69 0.19 -9.67 -4.31 0.0058
Year 3 -9.58 -4.86 0.38 -9.84 -3.67 0.01 
Health Distress 
change from 
baseline 
Year 4 -9.88 -0.57 0.099 -10.09 -4.12 0.032 
Year 1 8.15 7.37 0.74 8.44 6.03 0.098 
Year 2 8.06 4.69 0.32 8.20 5.59 0.16 
Year 3 8.79 0.00 0.026 8.78 6.02 0.24 
Self-rated health 
change from 
baseline 
Year 4 7.72 9.09 0.79 7.96 3.99 0.12 
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Table S5: summary results of multivariate model (N=2,163). 
DASI Energy health distress Self-rated health Effect 
Estimate P Estimate p Estimate P Estimate p 
One unit increase in mean follow-up BMI  
(Between-person BMI difference, βBSBMI) -0.27 <0.001 -0.32 <0.001 0.24 <0.001 -0.34 <0.001
Within a person, one unit difference in each follow-up BMI measure from mean follow-up BMI 
(Within-person BMI difference, βWSBMI) 0.017 0.92 -0.39 0.017 
βWSBMI for baseline obese patients  -0.36 <0.001 -0.55 <0.001 
Quadratic βWSBMI for baseline obese patients  -0.055 0.044 -0.10 0.02 
βWSBMI for baseline non-obese patients  0.11 0.51 0.39 0.16 
Quadratic βWSBMI for baseline non-obese patients   -0.44 <0.001 -0.69 <0.001   
MI/stroke occurred in prior yr -2.36 <0.001 -1.64 0.12 2.52 0.046 -2.11 0.083 
Subsequent procedure occurred in prior yr -1.42 <0.001 -0.88 0.15 2.05 0.0046 -0.19 0.78 
*P value for quadratic within-person BMI change: 0.0013 for DASI and 0.0013 for Energy. P value for interaction between baseline obesity and 
within-person BMI change: 0.0031 for DASI and <0.001 for Energy. P value for interaction between MI/stroke occurred in prior yr and within-
person BMI change: 0.0071 for DASI 
*Model control for randomized treatment, stratum, time, baseline HRQoL, sex, race, smoking, age, geographic region, angina, insulin use, history 
of hypertension, MI, CHF, stroke, non-coronary artery disease, renal dysfunction, clinical neuropathy, and missing data pattern. 
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9. Conclusion 
The three HRQoL research topics in this dissertation represent the two end of 
epidemiology study spectrum—from pilot observational study to randomized clinical trial. 
As a Ph.D student, I am fortunate to have both opportunities. In conducting the 
observational cohort study, I had the opportunity to manage an entire study—from 
Institutional Review Board approval to accounting, from writing the study proposal to 
data collection, data analysis and drafting manuscript for publication. In working with 
BARI 2D, one of the most rigorously designed and conducted large scale randomized 
clinical trials, I had the opportunity to apply advanced statistical methods for longitudinal 
health status analysis, and gain the important knowledge of the different aspects in a 
randomized clinical trial, such as organization, implementation, and collaboration. 
Meditation is often used as a supportive therapy to relief stress and discomfort 
caused by regular medical therapy.  Thus, in the first paper, using HRQoL measures as 
the treatment outcome is clinically relevant. HRQoL measures are commonly 
continuous in scale and inexpensive to implement which makes them appealing as 
outcomes for small studies. Despite the limitations of pilot studies, results from paper 
one are informative and supportive of the beneficial effect of Sahaja Yoga Meditation on 
HRQoL.  
HRQoL research in a large scale randomized clinical trial has a different but as 
important role. Class III or IV randomized clinical trials for treatment effectiveness 
generally compare an effective novel treatment to a well-established clinical practice, or 
compare two established  treatment strategies, as in BARI 2D. The goal of the trial is to 
detect small but significant differences between two treatment alternatives, and it is not 
uncommon for two treatments to demonstrate equal effect on primary clinical 
outcomes—indicating the two treatments are as good. Under such circumstances, 
HRQoL and economic comparisons become important, and the treatment which leads 
to a better quality of life or which is more affordable will be preferred. In the randomized 
clinical trial for treatment efficacy, important clinical variables are measured and 
monitored repeatedly over time in a large study population, which makes it possible to 
test hypotheses other than the main treatment comparison. In BARI 2D, we are able to 
test whether the comparative effect of the randomized treatments on clinical and 
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HRQoL outcomes depend on age. We are also able to investigate the longitudinal 
association between change in BMI and HRQoL for patients receiving standard 
treatment regimens.  
Selection bias remains the main threat of validity in observational study. In the 
meditation research, since the participants selected their own treatment, we cannot fully 
distinguish the extent of difference in HRQoL that is contributable to meditation therapy 
and the extent contributable to unobserved characters of the participants. Such concern 
is minimized in randomized trial, since treatment is allocated randomly, and the effect of 
unobserved confounders is theoretically balanced out. However, different kinds of 
selection bias exist in randomized trials. The potential sources of selection bias derive 
from the eligibility criteria and missing values. Patients with either very low or very high 
levels in risk factors but meet the eligibility criteria may have different physiological or 
pathological response. This should be kept in mind while interpreting study results to 
groups of patients with extreme values. For example, participants who were 
underweight but had both heart disease and type 2 diabetes to be eligible for BARI 2D 
may have a different disease mechanism that influences their HRQoL response. Thus, 
the association between BMI and HRQoL observed in the study may not fully apply to 
underweight or extremely obese individuals. Missing data is a common concern for all 
HRQoL studies, in the dissertation, missing data is small in the meditation study due to 
the manageable sample size and brief follow-up time. In large scale randomized trial 
with long-term follow-up, missing data is inevitable. However, if the missingess is small 
and the mechanism of missing is well understood, the effect of missing data can be 
effectively managed by current analytical methods. 
To address the limitations of the meditation study, I incorporated a proposal for a 
randomized clinical trial to better evaluate the health benefit of Sahaja Yoga Meditation 
as a final chapter in this dissertation. 
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10. Study proposal: A randomized trial investigate Sahaja Yoga Meditation and 
reduced sodium DASH diet for prehypertension control 
10.1 SPECIFIC AIMS 
Hypertension remains a leading cause of mortality and morbidity. High blood 
pressure was the primary or contributing cause of death in United States.64,65 
Prehypertensive individuals are at an increased risk of developing clinical hypertension, 
and interventions for blood pressure control in this high risk group are of clinical and 
public health importance.  
Previous research has shown the positive effect of Sahaja Yoga Meditation in 
treatment of essential hypertension. The proposed study aims to evaluate the effect of 
Sahaja Yoga Meditation on lowering blood pressure in prehypertensive individuals. The 
study also investigates potential synergic effect of Sahaja Yoga Meditation and reduced 
sodium DASH diet on blood pressure control.  
The proposed study uses a randomized trial design with the primary outcome being 
change in systolic blood pressure during eight-week follow up. Secondary outcomes 
include change in diastolic blood pressure and health related quality of life. 
10.2 BACKGROUND AND SIGNIFICANCE  
10.2.1 Hypertension Disease Burden 
In 2000, worldwide prevalence of hypertension was 26.4%, translating into about 
972 million adults live with hypertension. It is estimated that by year 2025, about one in 
every three adults in the world will have hypertension, a disease burden of 1.56 billion 
people.63 In the 1999-2002 NHANES survey, hypertension prevalence was 31.3% in the 
United States, with an estimated adult hypertensive population of 65 million.64,65 The 
overall death rate from high blood pressure was 18.1 per 100,000 in United States 
during 2003, and high blood pressure was the contributing cause of 11.31% deaths.65 In 
2006, the estimated direct and indirect cost of high blood pressure was 63.5 billion 
dollars.64 The mean total costs were $ 146,500 among mildly hypertensive and $ 
219,300 among severely hypertensive men.109 
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Hypertension serves as a major risk factor for cardiovascular disease and stroke. 
60% of the population-attributable risk of stroke is explained by hypertension, and 91% 
cognitive heart failure cases are with a history of hypertension. 110  Hypertensive 
individuals have four times greater risk of stroke, and two to three times higher risk of 
developing cognitive heart failure than individuals with normal blood pressure.64  
Prehypertension is a state of elevated blood pressure, which is not yet reaching 
clinical hypertension. In the seventh report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII), 
prehypertension is defined as a systolic blood pressure between 120 to 139 mmHg and 
a diastolic blood pressure between 80 to 89 mmHg.111 Prehypertensive individuals have 
a higher risk for developing hypertension. The Framingham Heart Study reported a two 
to four times higher odds of hypertension among participants with baseline blood 
pressure between 120-129/80-84 mmHg to those with below 120/70 mmHg. And a high 
normal blood pressure (130-139/85-89 mmHg) was associated with a five to twelve 
times higher odds of hypertension during four-year follow up.112 
10.2.2 Management for Prehypertension 
Prehypertension is not a disease category, but to identify individuals at high risk of 
developing hypertension. In the JNC VII guideline, lifestyle modification is 
recommended for managing prehypertension; strategies include weight loss, salt 
reduction, exercise and dietary intervention.111 The effect of lifestyle modifications on 
lowering blood pressure has been reported in previous studies. The trials of 
Hypertension Prevention reported a 21% reduction in hypertension incidence in 
participants assigned to a weight loss counseling intervention to usual care.113 Whelton 
et al114 conducted a meta-analysis involving 1,108 normotensive persons enrolled in 27 
randomized controlled trials, and reported a significant mean 4.04 mmHg systolic blood 
pressure reduction in those assigned to aerobic exercise than controls. Xin et al 115 
summarized results of 15 randomized controlled trials and reported a dose-response 
association between the decreased alcohol consumption and reduction in blood 
pressure. 
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The Dietary Approaches to Stop Hypertension (DASH) trial reported a significant 
3.5 mmHg systolic blood pressure reduction in normotensive or hypertensive individuals 
assigned to the DASH diet, as compared to a typical diet in the general US 
population.116 The DASH diet is comprised with a higher intake of fruits, vegetables, and 
low-fat dairy products, while containing small amounts of red meat, sweets, sugar-
containing beverages, and low total fat intake, especially for saturated fat and 
cholesterol.  
A reduced sodium intake is also associated with a small but significant reduction in 
systolic blood pressure in normotensive persons. In a meta-analyses conducted by 
Cutler et al, results from 12 randomized controlled trials in normotensive participants are 
summarized, and an average reduction of a 77 mmol/d in dietary sodium was 
associated with a significant mean 1.9 mmHg decrease in systolic blood pressure.117    
To investigate the effect of combining a healthy diet and low salt intake, the DASH-
Sodium study investigated the blood pressure lowing effect of DASH diet together with 
different dietary sodium intake levels in normotensive or hypertensive participants. The 
trial reported a 7.1 mmHg reduction in systolic blood pressure in DASH diet and 
reduced sodium intake group to control diet and high sodium intake group. 118 The 
magnitude of reduction is similar to or greater than a single drug therapy.119,120As a 
result, in the United States national guidelines for hypertension prevention, DASH diet 
and reduced dietary sodium intake (≤ 2.3 g sodium or 5.8 g sodium chloride) are 
recommended.111 
 
10.2.3  Outcomes for prehypertension treatment evaluation 
    The systolic blood pressure marked the maximum force generated by circulating 
blood on the vascular wall, while the diastolic blood pressure marked the minimum force. 
In the conditions of atherosclerosis or arterial stiffness in aging arteries, more workload 
is required for the heart to counterbalance the additional resistance in the hardened 
arteries. The resulting increment in blood pressure is more obvious in systolic than 
diastolic blood pressure, since diastolic blood pressure is more related to peripheral 
resistance.121 The Framingham study showed that using diastolic than systolic blood 
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pressure to define hypertension may underestimate the number of patients requiring 
treatment.122 Thus, in clinical trials, systolic blood pressure is a preferable measurement.  
In patients with chronic conditions, treatment effectiveness can be substantially 
altered after accounting for Health-related quality of life (HRQoL).7,8 Therefore, HRQoL 
is commonly assessed in clinical trials as a secondary outcome of interest.  
10.2.4. The Effect of Sahaja Yoga Meditation on Lowering Blood Pressure 
Sahaja Yoga Meditation is a simple method that helps individuals from any 
background to achieve tranquility and inner peace.51 The therapeutic effect of Sahaja 
Yoga Meditation is achieved in meditation, characterized by the state of mental silence 
where one can better introspect, address and resolve the distress caused by negative 
thoughts, emotions or behaviors. Previous clinical research reported a mean 12.4 
mmHg systolic blood pressure decrease and mean 10.8 mmHg diastolic blood pressure 
decrease in hypertensive patients received 4 months Sahaja Yoga Meditation with their 
anti-hypertension drug treatment than patients received anti-hypertension drug 
treatment only.53 In a recent observational cohort study, a significant mean 12 mmHg 
systolic blood pressure reduction was observed in hypertensive patients received 
Sahaja Yoga Meditation treatment than those receiving conventional treatment. Sahaja 
Yoga Meditation therapy was associated with significant increase in quality of life. 
Previous studies were subject to several limitations, including small sample sizes 
and confounding by indication in observational study, in which patients selected 
treatments based on individual or clinical difference that are difficult to rule out in non-
randomized study design.  
To address the limitations and better assess the effect of Sahaja Yoga Meditation 
on blood pressure control, the proposed study uses a randomized clinical trial with a two 
by two factorial design to compare Sahaja Yoga Meditation and reduced sodium DASH 
diet in blood pressure control for prehypertension. The secondary outcome in the study 
is health related quality of life (HRQoL). The proposed study also investigates possible 
synergy of meditation and dietary intervention on blood pressure reduction and quality 
of life.   
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10.3 STUDY HYPOTHESES: 
10.3.1 Primary Hypothesis 
Change in systolic blood pressure in prehyertensive individuals assigned to Sahaja 
Yoga Meditation is different than those who are assigned to wait-list control. 
 
10.3.2 Secondary Hypotheses 
1) Change in HRQoL in prehyertensive individuals assigned to Sahaja Yoga Meditation 
is different than those who are assigned to wait-list control. 
2) Change in systolic blood pressure and HRQoL in prehyertensive individuals 
assigned to Sahaja Yoga Meditation with control diet is similar to that in 
prehypertensive individuals assigned to reduced sodium DASH diet with wait-list 
control. 
3) Change in systolic blood pressure and HRQoL in prehyertensive individuals 
assigned to a combination of Sahaja Yoga Meditation and reduced sodium DASH 
diet is different from those who are assigned to either Sahaja Yoga Meditation with 
control diet or to the reduced sodium DASH diet with wait-list control. 
   
10.4 STUDY DESIGN AND METHODS 
The overall design of the study is an eight-week randomized two by two factorial trial in 
untreated prehypertensive individuals. 
10.4.1 Participants and Recruitment 
1) Inclusion criteria: prehypertensive individuals age more than 21 years. 
Prehypertension is defined as entry blood pressure of 130 to 139/ 89 or 139/85 to 
89 mm Hg.   
2) Exclusion criteria: individuals receive anti-hypertensive treatment at baseline, 
myocardial infarction, stroke or transient ischemic attack within the last year, or 
malignancy, pregnancy; the use of medications that affect blood pressure; 
unwillingness to stop taking vitamin and mineral supplements or antacids containing 
magnesium or calcium; renal insufficiency; and an alcoholic-beverage intake of more 
than 14 drinks per week.  
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3) Recruitment 
The primary recruitment strategy is focus on patients seeking care for 
prehypertension, and recruits them from the clinic in the hospital or through referrals 
by family physicians. To recruit individuals with asymptotic prehypertension, mass 
mailing of brochures, work-site and community-based screenings are to be used for 
recruitment. 
   
10.4.2 Intervention 
Each of the two intervention strategies in the study comprises two treatment groups. 
The meditation intervention includes the wait-list control group and Sahaja Yoga 
Meditation group. The dietary intervention includes control diet group and reduced 
sodium DASH diet group.  
Meditation Intervention  
1. Control group: wait-list control. 
There is no intervention for the wait-list control participants during the eight-week 
intervention period. Participants in the control group will receive the same assessments 
as the Sahaja Yoga Meditation group.   
2. Sahaja Yoga Meditation group 
The Sahaja Yoga Meditation program is a weekly 90-minute session, guided by 
Sahaja Yoga instructors. The session is composed of two period of 15 to 20 minutes 
meditation, information about how to meditate and sharing of experience. The instructor 
directs participants to become aware of the state of meditation within themselves by 
becoming silent and focusing their attention inside. Each participant will be asked to 
conduct shorter meditation sessions at home twice a day, and record daily meditation in 
the study diary.58  
Dietary Intervention 
1.   Control Diet 
The control diet has the nutrient composition of the typical diets in the general 
American population. The macronutrient profile and fiber content correspond to the 
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average consumption, while the potassium, magnesium, and calcium levels are close to 
the 25th percentile of U.S. consumption.123 The sodium content in the diet is 100 mmol. 
 
2, Reduced Sodium DASH Diet118 
The combination diet is rich in fruits, vegetables, and low-fat dairy foods and has 
reduced amount of saturated fat, total fat, and cholesterol. This diet provides potassium, 
magnesium, and calcium at levels close to the 75th percentile of U.S. consumption, 
along with high amounts of fiber and protein.118 The sodium content in the diet is 50 
mmol.  
The proposed study adopted the controlling feeding strategy from the DASH 
study.116,118 The design of the menus are to be based on commonly available foods to 
meet the nutritional requirement of each diet. Food is to be prepared in research 
kitchens of every study center according to a common protocol. All centers will be 
instructed to use the same brand of a given food item for standardization of the diets.116 
A seven-day menu cycle with 21 meals at four calorie levels of 1600, 2100, 2600, 
and 3100 kcal will be designed to meet the nutritional needs of the participants while 
keeping their weight steady during the period of study.116 Participants will be requested 
to have either lunch or dinner on site during weekdays. At the on-site meal, the 
participants will be given meals to be consumed off site. Weekend meals will be given 
on Fridays for participants to consume off site.116 The weight of each participant will be 
measured every weekday and kept stable by changing calorie levels and by adding 
100-kcal snacks with nutrient contents that correspond to the assigned diets.116  
Participants will be instructed to drink no more than three caffeinated beverages 
and no more than one alcoholic beverage per day. At each onsite meal, the subjects will 
record their beverages and additional salt intake, any non-study foods items they take 
or study food items they do not take.118 
 
10.4.3 Measurement 
Measurement for Blood Pressure 
Sphygmomanometer remains the gold standard in measuring blood pressure. In 
the proposed study, blood pressure is measured using a calibrated sphygmomanometer 
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according to its standardized protocol. Systolic blood pressure is measured as the point 
of appearance (phase I) of Korotkoff sounds; diastolic blood pressure is measured as 
the point of disappearance (phase V). Measurements will be taken with participants in 
the sitting position after five minutes of rest. The readings are to be taken from 3 
consecutive measures, which are five minutes apart.  
 
Assessing Baseline Demographic and Clinical Profile 
Demographic data and clinical history of each patient will be collected at baseline 
using a structured questionnaire. The Stanford 7-Day Physical Activity Recall 
questionnaire will be administered once during screening.124 At baseline, weight, height, 
and skinfold thickness will be measured.  
Laboratory Tests for Blood and Urine Sample 
Routine laboratory tests are recommended by JNC VII in hypertension control, 
such as urinalysis and blood assay for glucose and hematocrit; serum potassium, 
creatinine, calcium, and a fasting lipoprotein profile. For individuals with diabetes or 
kidney disease, annual urinary albumin excretion or albumin/creatinine ratio monitoring 
are also recommended.105 In the study, fasting blood samples will be drawn at baseline 
and the end of eight-week follow up for analyzing serum potassium, creatinine, calcium 
level, and a fasting serum profile of glucose, cholesterol, triglycerides, high-density and 
low-density lipoprotein cholesterol. A urine sample will be collected from each 
participant at baseline and the end of eight week follow up to obtain urinary sodium, 
potassium, phosphorus, urea nitrogen, albumin excretion, albumin/creatinine ratio. The 
blood and urinary samples will be assayed in corresponding core laboratories.  
Health Related Quality of Life Measurements 
HRQoL is measured by the WHOQOL-BREF.19 The WHOQOL-BREF is 26-item 
self-administered questionnaire measuring quality of life from four domains including 
physical health, psychological, social relationship and environment. Two summary 
questions measure overall quality of life and general health.19 The time reference for the 
questions is two weeks. The questionnaire generated four domain specific scores, 
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ranging from 4-20 or 0-100, and a higher score indicate better quality of life. A multi-
countries field trial of WHOQOL-BREF demonstrates good internal consistency, 
reliability and constructs validity.125 For healthy people, the questionnaire takes about 
five minutes to complete.  
 
10.4.4 Outcomes 
1) The primary outcome of the study is the change in resting systolic blood pressure. 
Change is defined as the longitudinal difference in blood pressure during follow-up. 
Three consecutive blood pressure measurements are to be averaged as the blood 
pressure result at each weekly follow up visit.  
2) The secondary outcomes of interest are changes in diastolic blood pressure during 
follow up and HRQoL results at the end of follow up.  
 
10.4.5 Randomization   
A computer program is proposed to be used to generate the allocation sequence 
(StataCorp LP, College Station, TX, www.stata.com). The program generates random 
permuted blocks using blocks sizes 4, 6, and 8. An individual not affiliated with the 
conduct of the study will enter a seed number for the program to produce the allocation 
sequence for preparation of allocation envelopes.  Consented participants will be 
randomly allocated to one of the following groups in a 1:1 ratio: 
Group 1:  Sahaja Yoga Meditation and reduced sodium DASH diet 
Group 2:  Sahaja Yoga Meditation and control diet 
Group 3:  Wait-list control and reduced sodium DASH diet 
Group 4:  Wait-list control and control diet 
Randomization is stratified by clinical site and by self report type 2 diabetes at 
screening phase of the study.  
10.4.6 Patient subgroups 
The primary treatment comparisons will be tested in predetermined subgroups. The 
priori subgroups are defined by baseline characters, including type 2 diabetes, sex, and 
obesity categories defined by body mass index.  
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10.4.7 Trial Implementation 
The trial is designed to have three phases—the screening, run-in, and intervention 
phases. If an individual desires to enter the study, the study will be explained in detail.  
Informed consent will be obtained by the study staff or investigator. After obtaining 
informed consent, an investigator or research assistant will review the inclusion and 
exclusion criteria of the individual. For each treatment group, during screening visits, 
trained and certified staff will measure the standard blood pressure of the participants 
with a calibrated sphygmomanometer. Three consecutive measures with five minutes 
interval between measures will be obtained after the subjects rested for five minutes in 
the seated position. Questionnaire survey on baseline characteristics, clinical history, 
prehypertension risk profile and health related quality of life will be administrated during 
the screening visit. 
The run-in phase is a two-week period when all consented participants will be given 
control diet. Weekly blood pressure measurements composed of three consecutive 
measures, one fasting blood sample, one 24-hour urine sample, and information on the 
symptom questionnaire and HRQoL will be collected from each participant. During the 
second week, the participants will be randomly assigned to one of four intervention 
strategy combinations and learned of their assignments (meditation and diet) on the first 
day of the intervention. 
The intervention phase is an eight-week period active intervention, in which the 
subjects will be following their assigned intervention. During the first six weeks, each 
week trained staff members who are blinded to treatment diet assignment will measure 
the blood pressure of study participants. Three consecutive measures with five minutes 
interval between measures will be obtained after the subjects rested for five minutes in 
the seated position. During the last two weeks, in addition to weekly blood pressure 
measurements, one fasting blood sample, one 24-hour urine sample, and information 
on the symptom questionnaire, HRQoL and physical-activity-recall questionnaire will be 
collected from the participants.  
10.4.8 Statistical Analysis 
All analyses comparing the effect of randomized treatment assignment on 
outcomes will be based on the intention-to-treat principle. The significance level of 
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randomized treatment comparisons between the four groups is set to be a 2-sided p 
value of 0.05. For treatment comparisons within the pre-specified subgroups, a 2-sided 
p value of 0.01 is used to correct for multiple testing. In multivariable models, interaction 
between randomized treatment and pre-specified subgroups will be tested. 
To control for the correlation from repeated measures within each participant, linear 
mixed effect model is proposed to be used for primary outcome comparisons. For 
HRQoL analysis, since quality of life measured at baseline and the end of follow-up, in 
the analysis, follow-up quality of life measures will be used as the outcome, and adjust 
for baseline values. The baseline blood pressure and HRQoL measures will be the 
average of measurements obtained during both the screening and run-in phases.  
The missing outcome measure is defined when a patient is alive and participating 
in the study but does not provide outcome measures expected per protocol. With the 
application of mixed effect model with the restricted maximum likelihood algorithm, the 
assumption is missing at random. However, if missing outcomes is substantial and it is 
suspected that missing is not at random, a random-effects pattern mixture models will 
be applied for analysis under the framework of mixed effect models.27   
10.4.9 Sample Size Estimation  
Sample size is calculated based on the primary hypothesis for differernce in 
reduction in systolic blood presure in participants randomly assigned to Sahaja Yoga 
Meditation and wait-list control. According to the pilot data, the standared deviation of 
Sahaja Yoga Meditation on change in systolic blood pressure is 13.2 mmHg. In addition, 
previous studies reported a 30% dropout rate in research applied Sahaja Yoga 
Meditation on asthma management,56 and a 76% retention rate in the study of children 
with attention deficit-hyperactivity disorder.58 Meanwhile, high adherence was reported 
in the DASH-Sodium trial, where 95 percent of the participants assigned to the DASH-
diet group and 94 percent of those assigned to the control-diet group completed the 
study and provided blood-pressure measurements during each intervention period.118 As 
a result, assume a dropout rate of 30 percent, 10 percent missing data, a Type I error 
rate of 0.05 and a Type II error rate of 0.1, the sample size estimates for testing the 
primary hypothesis according to different effect size are summarized in table 2. The 
proposed study population is 300 participants in each group of the primary treatment 
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comparison, which equals to a total of 600 participants. The estimated power is 90% for 
the study to detect a 4 mmHg or more difference in systolic blood pressure change 
between Sahaja Yoga meditation and wait-list control.  
Effect size (mmHg) Crude estimates
Adjusted by dropout  
and missing data rates 
3 330 524 
4 186 295 
5 119 189 
6 83 132 
 
10.4.10 Timeline 
The duration of the study is estimated to be 15 months, including 6 months recruiting, 3 
months conducting the study, and 6 months data management and analysis.  
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